1,5-naphthyridine protac derivatives as KRAS oncoprotein inhibitors

Abstract

The present invention is directed to inhibitors of Kirsten rat sarcoma virus (KRAS) oncoproteins, and more particularly to certain 1,5-napthyridine PROTAC derivatives PROTAC represented by the Formula (I) as well as compositions comprising Formula (I) and methods of using the compound of Formula (I) for the treatment or prevention of a disease, disorder, or medical condition mediated through KRAS, especially the KRAS G12C and KRAS G12D oncoproteins.

Description

[0001] Attorney Docket No. BPR0115PCT

[0002] 1,5-NAPHTHYRIDINE PROTAC DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS This Applications claims priority to U.S. Provisional Patent Application Serial No.

[0004] 63 / 760,294 filed February 19, 2025, which is incorporated by reference herein in its entirety.

[0005] BACKGROUND OF THE INVENTION

[0006] Field of the Invention

[0007] The present invention is directed to inhibitors of Kirsten rat sarcoma virus (KRAS) oncoproteins, and more particularly to certain 1,5-napthyridine PROTAC derivatives, compositions and methods for the treatment or prevention of a disease, disorder, or medical condition mediated through KRAS, especially the KRAS G12C and KRAS G12D oncoproteins. The diseases include various cancers.

[0008] Brief Description of the Related Art

[0009] Ras is a superfamily of small guanosine triphosphate (GTP) binding proteins consisting of various isoforms. Ras genes can mutate into oncogenes that are associated with numerous cancers such as lung, pancreas, and colon. Ras is one of the most frequently mutated oncogenes. KRAS, (Kirsten rat sarcoma virus) an isoform of Ras, is one of the most frequently mutated Ras genes, comprising approximately 86% of all known mutations. KRAS functions as an On / Off switch in cell signaling. KRAS proteins are GTPases that operate between inactive (GDP-bound) and active (GTP -bound) states to control a variety of functions, including cell proliferation. However, mutated KRAS proteins lead to uncontrolled cell proliferation and cancer. The KRAS-4B proteoform is the major isoform in cancers of the colon (30-40%), lung (15-20%) and pancreas (90%) (Liu, P. et al., Acta Pharmaceutica Sinica B 2019, 9 (5), 871-879). Consequently, inhibitors of mutated KRAS proteins binding to GTP represent potential therapeutic agents for the treatment of various cancers.

[0010] Past attempts to design KRAS oncoprotein inhibitors have been mostly unsuccessful, due in large part to the high affinity of the KRAS oncoproteins for GTP. However, more recent approaches that target KRAS G12C and KRAS G12D have shown more promise. This mutation exists in roughly 50% of lung cancers and approximately 10-20% of all KRAS G12 mutations. The cysteine residue of the mutation is positioned within the active site suchAttorney Docket No. BPR0115PCT

[0011] that the sulfhydryl functionality can form a covalent bond with a suitably functionalized bound ligand (Liu, Acta Pharmaceutica Sinica B 2019). This approach has identified irreversible, covalent inhibitors of KRAS G12C that are undergoing clinical study. The KRAS G12D mutation is present in approximately 4% of all non-small cell lung cancers, 13% of all colorectal cancers, 25% of pancreatic ductal adenocarcinomas, and 1.7% of small cell lung cancers (Cerami, E. and Sawyers, C. L. Cancer Discovery 2017, 7 (8), 818-831). Thus, inhibitors to KRAS G12D would also be beneficial for treatment of patients with these mutations.

[0012] A proteolysis targeting chimera (PROTAC) is a molecule that can remove specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. A heterobifunctional molecule with two active domains and a linker, PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein via the proteasome. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.

[0013] Given the prominent role that KRAS G12C and KRAS G12D play as a driver of many malignancies, a need for new KRAS G12C and G12D inhibitors with improved selectivity, safety, and efficacy profiles exists.

[0014] SUMMARY OF THE INVENTION

[0015] In one aspect, the present invention is directed to a compound of Formula I:

[0016] R2

[0017]

[0018] G Formula I

[0019] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, whereinAttorney Docket No. BPR0115PCT

[0020] A is chosen from aryl or heteroaryl optionally substituted with one or more of hydrogen, halogen, hydroxy, -Ci-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -C0-3 alky l(Cs-6 cycloalkyl), -C1-6 alkyl(halo), -Ci-6alkyl(OH), -O(Ci-4

[0021] alkyl), -C1-3 alkyl(Ci-4alkoxy), -CN, -CO2R4,

[0022] -CO2N(R4)2, -NO2, -N(R4)2, -P(O)(R5)2, -SR4, -S(O)R4, -SO2R4or a 5-6 membered heterocyclic ring;

[0023] Y and G may be the same or different and chosen from hydrogen, halogen, CM alkyl, CM perdeuteroalkyl, -(C0-2 alkyl)alkenyl, -(C0-2 alkyl)alkynyl, -(C0-2 alkyl)cycloalkyl, -CM haloalkyl, -O(Ci-4alkyl), -S(CM alkyl), -(Co-2 alkyl)cyano, -O(Ci-4haloalkyl) or -S(Ci- 4 haloalkyl);

[0024] L is a bond, O, S or NR4;

[0025] m is 0-2;

[0026] n is 0-2;

[0027] Z is C(R4)2or a cyclic compound chosen from C3-7 cycloalkyl, a saturated or partially unsaturated 4- to 7-membered nitrogen-containing ring, a saturated or partially unsaturated 7- to 10-membered nitrogen-containing bridged bicyclic ring, wherein the saturated or partially unsaturated 7- to 10-membered nitrogen-containing bridged bicyclic ring may be substituted by halogen, preferably F, or unsubstituted;

[0028] R1is chosen from hydrogen, hydroxy, halogen, -C1-3 alkyl, -C1-3 alkyl(OH), -C1-3 alkyl(halo), -C1-3 alkyl(Ci-3 alkoxy), -C1-3 alkyl(CN) or -C1-3 alkyl(P(O)R52);

[0029] R2is chosen from hydrogen, -C(O)CH=CH, -C(O)CF=CH or -C(O)CC1=CH with the proviso that when R2is hydrogen, then m is either 1 or 2;

[0030] R3is chosen from hydrogen, halogen, hydroxy, -C1-4 alkyl, -C2-4 alkenyl, -C2-4 alkynyl, -C0-3 alkyl(C -6 cycloalkyl), -CM alkyl(halo), -Ci-4alkyl(OH), -0(CM

[0031] alkyl), -C1-3 alkyl(Ci-3

[0032] alkoxy), -CN, -CO2R4, -CO2N(R4)2, -NO2, -N(R4)2, -PO(R5)2, -SR4,-S(O)R4, -SO2R4, or -(C0-3 alkyl)R6, a VHL E3 ligase ligand, or a Cereblon (CRBN) E3 ubiquitin ligase; R4is chosen from is chosen from hydrogen, C alkyl, aryl or heteroaryl;

[0033] R5is chosen from hydrogen, hydroxy, CM alkyl, aryl, heteroaryl, CM alkoxy, aryloxy or heteroaryloxy;

[0034] R6is chosen from N(R4)2or a 4- to 7-membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group N, O and S; and

[0035] R7is chosen from hydrogen or halogen. In one embodiment, R7is fluorine.Attorney Docket No. BPR0115PCT

[0036] PROTACs have emerged as a new and promising modality in drug discovery.

[0037] PROTACs are constructed from two ligands that are connected by a linker. The nature of this linker, length and composition, and the attachment site of the linker to each ligand affects the affinity of ligands to each of its binding partners and the relative orientation of the two proteins to one another in the ternary complex. These bifunctional molecules simultaneously engage a protein of interest (POI) and an E3 ligase, forming a ternary complex, enabling the E3 ligase to ubiquitinate the POI on proximal lysine residues. The ubiquitinated POI is subsequently recognized and degraded by the 26S proteasome. A major advantage of target degradation is the elimination of scaffolding roles that are not typically attenuated by traditional small-molecule inhibitors.

[0038] In another aspect, the present invention is directed to PROTAC-mediated degradation as a complementary strategy to modify KRAS.

[0039] In another aspect, the present invention is directed to the compound of Formula I with a PROTAC component to achieve degradation through "hijacking" the cell’s ubiquitin-proteasome system (UPS) by bringing together the target protein and an E3 ligase.

[0040] In another aspect the present invention is directed to a KRAS G12C or G12D oncogenic inhibitor-PROTAC capable of degrading exogenous KRAS G12C or KRAS G12D.

[0041] In another aspect, the present invention is directed to a pharmaceutical composition comprising the compound of Formula I, or a salt, solvate, or prodrug thereof, together with a pharmaceutically acceptable carrier.

[0042] In another aspect, the present invention is directed to a method of treating a disease, disorder, or medical condition in a patient, comprising the step of providing to a patient in need thereof a therapeutic agent, wherein the therapeutic agent is a compound of Formula I or a salt, solvate, or prodrug thereof.

[0043] BRIEF DESCRIPTION OF THE FIGURES FIGs. 1 and 2 depict Western Blot band density analysis of Compound 3b.

[0044] FIGs. 3 and 4 depict gel profiles of the Western Blot shown in Figs. 1 and 2.

[0045] Fig. 5 depicts Western blot analysis of LC-2 in NCI-H358 and MIA PaCa-2 cells. Fig. 6 depicts Western blot analysis of Compound 2b in NCI-H358 and MIA PaCa-2 cells.Attorney Docket No. BPR0115PCT

[0046] Fig. 7 depicts Western blot analysis of Compound lb in NCI-H358 and MIA PaCa-2 cells.

[0047] DETAILED DESCRIPTION OF THE INVENTION TERMINOLOGY

[0048] Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.

[0049] The terms “a” and “an” do not denote a limitation of quantity but rather denote the presence of at least one of the referenced items. The term “or” means “and / or”. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”).

[0050] Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable.

[0051] All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention as used herein. Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art of this disclosure.

[0052] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims are introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group.

[0053] All compounds are understood to include all possible isotopes of atoms occurring in the compounds. Isotopes include those atoms having the same atomic number but different mass numbers and encompass heavy isotopes and radioactive isotopes. By way of generalAttorney Docket No. BPR0115PCT

[0054] example, and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include11C,13C, and14C. Accordingly, the compounds disclosed herein may include heavy or radioactive isotopes in the structure of the compounds or as substituents attached thereto. Examples of useful heavy or radioactive isotopes include18F,15N,180,76Br,125I and131I.

[0055] All formulae disclosed herein include all salts of such Formulae.

[0056] The opened ended term “comprising” includes the intermediate and closed terms “consisting essentially of” and “consisting of.”

[0057] The term “substituted” means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom’s normal valence is not exceeded. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent.

[0058] A dash (“-“) that is not between two letters or symbols is used to indicate a point of attachment for a substituent.

[0059] “Alkyl” includes both branched and straight chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms, generally from 1 to about 8 carbon atoms. The terms Ci-6 alkyl, Ci-Ce alkyl and Cl - C6 alkyl as used herein all indicate an alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms. Other embodiments include alkyl groups having from 1 to 8 carbon atoms, 1 to 4 carbon atoms or 1 or 2 carbon atoms, e.g., Ci-8 alkyl, Ci-4 alkyl, and C1-2 alkyl. When Co-n alkyl is used herein in conjunction with another group, for example, -Co-4 alkyl(phenyl), the indicated group, in this case phenyl, is either directly bound by a single covalent bond (Co alkyl), or attached by an alkyl chain having the specified number of carbon atoms, in this case 1, 2, 3, or 4 carbon atoms. Alkyls can also be attached via other groups such as heteroatoms as in -OC0-4 alkyl(Cs-7 cycloalkyl). Examples of alkyl include, but are not limited to, methyl, ethyl, zz-propyl, isopropyl, n-butyl, 3-methylbutyl, Fbutyl, / / -pentyl, and sec-pentyl.

[0060] “Alkoxy” is an alkyl group as defined above with the indicated number of carbon atoms covalently bound to the group it substitutes by an oxygen bridge (-O-). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, / -propoxy, n-butoxy, 2-butoxy, / -butoxy, / / -pentoxy. 2-pentoxy, 3 -pentoxy, isopentoxy, neopentoxy, / / -hexoxy. 2-hexoxy, 3-hexoxy, and 3- methylpentoxy. Similarly, an “alkylthio” or a “thioalkyl” group isAttorney Docket No. BPR0115PCT

[0061] an alkyl group as defined above with the indicated number of carbon atoms covalently bound to the group it substitutes by a sulfur bridge (-S-). Similarly, “alkenyloxy”, “alkynyloxy”, and “cycloalkyloxy” refer to alkenyl, alkynyl, and cycloalkyl groups, in each instance covalently bound to the group it substitutes by an oxygen bridge (-O-).

[0062] “Halo” or “halogen” means fluoro, chloro, bromo, or iodo, and are defined herein to include all isotopes of same, including heavy isotopes and radioactive isotopes. Examples of useful halo isotopes include18F,76Br, and131I. Additional isotopes will be readily appreciated by one of skill in the art.

[0063] “Haloalkyl” means both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, generally up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.

[0064] “Haloalkoxy” is a haloalkyl group as defined above attached through an oxygen bridge (oxygen of an alcohol radical).

[0065] “Peptide” means a molecule which is a chain of amino acids linked together via amide bonds (also called peptide bonds).

[0066] “Pharmaceutical compositions” means compositions comprising at least one active agent, such as a compound or salt of Formula I, and at least one other substance, such as a carrier. Pharmaceutical compositions meet the U. S. FDA’s GMP (good manufacturing practice) standards for human or non-human drugs.

[0067] “Carrier” means a diluent, excipient, or vehicle with which an active compound is administered. A “pharmaceutically acceptable carrier” means a substance, e.g., excipient, diluent, or vehicle, that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier that is acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable carrier” includes both one and more than one such carrier.

[0068] A “patient” means a human or non-human animal in need of medical treatment. Medical treatment can include treatment of an existing condition, such as a disease or disorder or diagnostic treatment. In some embodiments the patient is a human patient.

[0069] “Providing” means giving, administering, selling, distributing, transferring (for profit or not), manufacturing, compounding, or dispensing.

[0070] “Treatment” or “treating” means providing an active compound to a patient in an amount sufficient to measurably reduce any disease symptom, slow disease progression orAttorney Docket No. BPR0115PCT

[0071] cause disease regression. In certain embodiments treatment of the disease may commence before the patient presents symptoms of the disease.

[0072] A “therapeutically effective amount” of a pharmaceutical composition means an amount effective, when administered to a patient, to provide a therapeutic benefit such as an amelioration of symptoms, decrease disease progression, or cause disease regression.

[0073] A “therapeutic compound” means a compound which can be used for diagnosis or treatment of a disease. The compounds can be small molecules, peptides, proteins, or other kinds of molecules.

[0074] A significant change is any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student’s T-test, where p < 0.05.

[0075] CHEMICAL DESCRIPTION

[0076] Compounds of the Formulae disclosed herein may contain one or more asymmetric elements such as stereogenic centers (e.g., asymmetric carbon atoms), stereogenic axes, rotamers with restricted rotation (e.g., atropisomers) and the like, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds can additionally be mixtures of diastereomers. For compounds having asymmetric centers, all optical isomers in pure form and mixtures thereof are encompassed. In these situations, the single enantiomers, i.e., optically active forms can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by resolution of the racemates. Resolution of the racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example, a chiral HPLC column. All forms are contemplated herein regardless of the methods used to obtain them.

[0077] All forms (for example solvates, optical isomers, enantiomeric forms, polymorphs, prodrugs, free base compound and salts) of the compounds of the invention may be employed either alone or in combination.

[0078] The term “chiral” refers to molecules, which have the property of non-superimposability of the mirror image partner.

[0079] “Stereoisomers” are compounds, which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0080] The term “solvate” refers to a chemical complex formed by the interaction of a solvent and a solute, such as the chemical compounds of the present invention.Attorney Docket No. BPR0115PCT

[0081] The term “prodrug” refers to a biologically inactive compound which can be metabolized inside the body to produce a drug.

[0082] A “diastereomer” is a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis, crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.

[0083] “Enantiomers” refer to two stereoisomers of a compound, which are non-superimposable mirror images of one another. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0084] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory.

[0085] A “racemic mixture” or “racemate” is an equimolar (or 50:50) mixture of two enantiomeric species, devoid of optical activity. A racemic mixture may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0086] A “chelating group” or “chelator” is a ligand group which can form two or more separate coordinate bonds to a single central atom, which is usually a metal ion. Chelating groups as disclosed herein are organic groups which possess multiple N, O, or S heteroatoms, and have a structure which allows two or more of the heteroatoms to form bonds to the same metal ion.

[0087] “Salts” include derivatives of the disclosed compounds in which the parent compound is modified by making inorganic and organic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriateAttorney Docket No. BPR0115PCT

[0088] base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts. In an embodiment, the compounds of the present invention are synthesized or isolated as trifluoroacetic acid (TFA) salts.

[0089] In one embodiment, the salt forms of the compounds of the present invention described above may include pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts include, but are not limited to, non-toxic mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, H00C-(CH2)n-C00H where n is 0-4, and the like. Lists of additional suitable salts may be found, e.g., in G. Steffen Paulekuhn, et al., Journal of Medicinal Chemistry 2007, 50, 6665 and Handbook of Pharmaceutically Acceptable Salts: Properties, Selection and Use, P. Heinrich Stahl and Camille G. Wermuth, Editors, Wiley-VCH, 2002.

[0090] In another embodiment, the invention pertains to a KRAS inhibitor with a PROTAC component, specifically a VHL (Von Hippel-Landau) E3 ligase ligand or a Cereblon (CRBN) E3 ubiquitin ligase complex, covalently bonded to the KRAS inhibitor wherein the PROTAC recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C and / or KRAS G12D degradation.

[0091] A Cereblon (CRBN) PROTAC forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). This complex ubiquitinates a number of other proteins and marks them for degradation via the proteasome.Attorney Docket No. BPR0115PCT

[0092] E3 ubiquitin ligases, which bind protein targets, leading to their ubiquitination and subsequent degradation, are attractive drug targets due to their exquisite substrate specificity.

[0093] In one embodiment, the compound of Formula II is represented by the structure:

[0094]

[0095] Formula II

[0096] including pharmaceutically acceptable salts, solvates, or prodrugs thereof.

[0097] In one embodiment, the compound of Formula II maybe synthesized from the compound of Formula III represented by the structure:

[0098] A.

[0099] "" TC'

[0100]

[0101] A J A., /

[0102] Formula III

[0103] The structure of Formula III is incorporated in the compound of Formula II with a VHL E3 ligase ligand to form the compound II PROTAC (shown above).

[0104] In an embodiment, the PROTAC is a VHL E3 ligase ligand, such as is (2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. In another embodiment, the PROTAC is a Cereblon (CRBN) E3 ubiquitin ligase complex.Attorney Docket No. BPR0115PCT

[0105] In other embodiments, the compounds of Formula I are represented by the structures la-c through 30a-c in Table 1. The descriptors a-c as defined for la-c apply to all of the compounds in Table 1:

[0106] Table 1

[0107] 0Y^ °Y^

[0108] N N N

[0109] ^N ^Y

[0110] ( Y X I I

[0111] Y if ^^N (Y ( 1 1X1 ( 1 1 X1

[0112] 1 JJ YY / X / VN O / Yl Y Y ^N Y>

[0113] N— /

[0114] w Y1 NY

[0115] w Y 1 NY w 1a; W=Me

[0116] 1b; W=VHL ligase 2a-c 3 a-c 1c; W=cereblon ligase

[0117] 1

[0118] °Y"^ °Y"%

[0119] N^YN:

[0120] N 1 N N / N\ / Y / ^. CN N ^1

[0121] ( XXXXX''~^INI ( I II I

[0122] ' XY "rY Y Y ^N ozYY ( X X I I J Y H Y '" N Y

[0123] Y 1 N Y\

[0124] NY Y

[0125] w w w 4a-c 5 a-c 6a-c

[0126] °Y^ °Y^ °Y^

[0127] N F N F N

[0128] / LX-NXI N

[0129] ( Y X I x ( X ( Y X I I YX / ^'' / XN'^'O / 'fY> X I I Y |Y^'''XY Yr'' '" YY Y |Yx / XN Oz' Y>

[0130] YY NY Y1 NY Y1 NY w w Y w OH

[0131] 9a-c, 7a-c 8 a-c

[0132]

[0133] Attorney Docket No. BPR0115PCT

[0134] N -. ”5 N ‘ ■•■'? Nr

[0135] / Cl / N. / Y / N. Y YkYTXX Nl O " Y\ 0 Y 3r X N1 O " YY 0003

[0136] Y^ iY '^ N O " YY YY, N— Y

[0137] Y Y YY, NY Y TY. N^ w w w7OH OH OH

[0138] 10a-c lla-c 12a-c

[0139] N. Y

[0140] N N

[0141] H2V

[0142] •n=\ > N (' YY 1 1X0 HN Y Y rNYrS

[0143] YY-Y'V " YY Y,, sKY Y Y Y / x YY^ N / Y |Y^^ N O " YY Y YY^" N O " YY — YYY NYrYYY N' / ^ OHwF w w

[0144] 13a-c 14a-c 15a-c

[0145] .. ■ Y ■■-'Y N N N

[0146] . F, N. Y / <5^ / CI / N. / Y ^^, Br / N^Y

[0147] ( 1 X 1 1CCx i CCCl i - Y r N o " YY Y^ Y '^N° ''YY YYXZ^NozYY YY NY YY N— / YY N— / W w W 16a-c 17a-c 18a-c

[0148] ■'- Y Y ■•''Y N N 1N

[0149] / x / / N. / Y / <^Y A. / x. ON. N. Y

[0150] OOcXiCCX x OOOOL - / x Y^YY^^ N O " YY Y Y N O " YY Y^ Y ~^ N O " YY

[0151] YY. N- / YY N- / YY. N- /

[0152] W W W

[0153] 19a-c 20a-c 21a-c

[0154]

[0155] Attorney Docket No. BPR0115PCT

[0156]

[0157] In an embodiment, the compound of Formula I can be depicted as Formula IV as represented by the structure:

[0158] H

[0159]

[0160] G

[0161] Formula IVAttorney Docket No. BPR0115PCT

[0162] including pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein

[0163] A is chosen from aryl or heteroaryl optionally substituted with one or more of hydrogen, halogen, hydroxy, -Ci-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -C0-3 alkyl(C -6 cycloalkyl), -C1-6 alkyl(halo), -Ci-6alkyl(OH), -O(Ci-4

[0164] alkyl), -C1-3 alkyl(Ci-4alkoxy), -CN, -CO2R4,

[0165] -CO2N(R4)2, -NO2, -N(R4)2, -P(O)(R5)2, -SR4, -S(O)R4, -SO2R4or a 5-6 membered heterocyclic ring;

[0166] Y and G may be the same or different and chosen from hydrogen, halogen, C1-4 alkyl, C1-4 perdeuteroalkyl, -(C0-2 alkyl)alkenyl, -(C0-2 alkyl)alkynyl, -(C0-2 alkyl)cycloalkyl, -C1-4 haloalkyl, -O(Ci-4alkyl), -S(Ci-4 alkyl), -(C0-2 alkyl)cyano, -O(Ci-4haloalkyl) or -S(C1-4haloalkyl);

[0167] L is a bond, O, S or NR4;

[0168] m is 0-2;

[0169] n is 0-2;

[0170] Z is C(R4)2or a cyclic compound chosen from C3-7 cycloalkyl, a saturated or partially unsaturated 4- to 7-membered nitrogen-containing ring, a saturated or partially unsaturated 7- to 10-membered nitrogen-containing bridged bicyclic ring, wherein the saturated or partially unsaturated 7- to 10-membered nitrogen-containing bridged bicyclic ring may be substituted by halogen, preferably F, or unsubstituted;

[0171] R1is chosen from hydrogen, hydroxy, halogen, -C1-3 alkyl, -C1-3 alkyl(OH), -C1-3 alkyl(halo), -C1-3 alkyl(Ci-3 alkoxy), -C1-3 alkyl(CN) or -C1-3 alkyl(P(O)R52);

[0172] R2is chosen from hydrogen, -C(O)CH=CH, -C(O)CF=CH or -C(O)CC1=CH with the proviso that when R2is hydrogen, then m is either 1 or 2;

[0173] R3is chosen from hydrogen, halogen, hydroxy, -C1-4 alkyl, -C2-4 alkenyl, -C2-4 alkynyl, -C0-3 alkyl(C3-6 cycloalkyl), -C1-4 alkyl(halo), -Ci-4alkyl(OH), -O(Ci-4

[0174] alkyl), -C1-3 alkyl(Ci~3 alkoxy), -C

[0175]

[0176] N, -CO2R4, -CO2N(R4)2, -NO2, -N(R4)2, -PO(R5)2, -SR4,-S(O)R4, -SO2R4, or -(C0-3 alkyl)R6, a VHL E3 ligase ligand, or a Cereblon (CRBN) E3 ubiquitin ligase; R4is chosen from is chosen from hydrogen, C1-4 alkyl, aryl or heteroaryl;

[0177] R is chosen from hydrogen, hydroxy, C1-4 alkyl, aryl, heteroaryl, C1-4 alkoxy, aryloxy or heteroaryloxy;

[0178] R6is chosen from N(R4)2or a 4- to 7-membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group N, O and S; and

[0179] R7is chosen from hydrogen or halogen, and halogen. In one embodiment, R7is fluorine.Attorney Docket No. BPR0115PCT

[0180] In one embodiment, Formula IV has the structure of Formula V:

[0181]

[0182] Formula V

[0183] including pharmaceutically acceptable salts, solvates, or prodrugs thereof.

[0184] In another embodiment, Formula V has the structure of Formula Va:Attorney Docket No. BPR0115PCT

[0185]

[0186] Formula Va

[0187] including pharmaceutically acceptable salts, solvates, or prodrugs thereof.

[0188] Compounds disclosed herein can be administered to a patient as the neat or freebase chemical but are preferably administered as a pharmaceutical composition. Accordingly, the invention encompasses pharmaceutical compositions comprising a compound or a salt (including a pharmaceutically acceptable salt) of a compound, such as a compound of Formula I, together with at least one pharmaceutically acceptable carrier. The pharmaceutical composition may contain a compound or salt of Formula I as the only active agent, but it preferably contains at least one additional active agent. In certain embodiments the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of a compound of Formula I and optionally from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form. The pharmaceutical composition may also include a molar ratio of a compound, such as a compound of Formula I, and an additional active agent. For example, the pharmaceutical composition may contain a molar ratio of about 0.5:1, about 1:1, about 2:1, about 3:1 or from about 1.5:1 to about 4:1 of an additional active agent to a compound of Formula I.Attorney Docket No. BPR0115PCT

[0189] Compounds disclosed herein may be administered orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers. The pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a pill, a capsule, a tablet, a syrup, a transdermal patch, or an ophthalmic solution. Some dosage forms, such as tablets and capsules, are subdivided into suitably sized unit doses containing appropriate quantities of active components, e.g., an effective amount to achieve the desired purpose.

[0190] Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert, or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.

[0191] Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents. Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin, talc, and vegetable oils. Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.

[0192] The pharmaceutical compositions I combinations can be formulated for oral administration. These compositions contain between 0.1 and 99 weight % (wt%) of a compound of Formula I and usually at least about 5 wt% of a compound of Formula I. Some embodiments contain from about 25 wt% to about 50 wt% or from about 5 wt% to about 75 wt% of the compound of Formula I.

[0193] TREATMENT METHODS

[0194] The compounds of Formula I PROTAC (for example the compound of Formula II), as well as pharmaceutical compositions comprising the compounds, are useful for diagnosis or treatment of a disease, disorder, or medical condition mediated through KRAS, especially the KRAS mutants G12C and G12D, and including various cancers, such as glioma (glioblastoma), acute myelogenous leukemia, acute myeloid leukemia, myelodysplastic / myeloproliferative neoplasms, sarcoma, chronic myelomonocytic leukemia,Attorney Docket No. BPR0115PCT

[0195] non-Hodgkin lymphoma, astrocytoma, melanoma, non-small cell lung cancer, cholangiocarcinomas, chondrosarcoma, colon cancer or pancreatic cancer.

[0196] According to the present invention, a method of KRAS-mediated diseases or conditions comprises providing to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I. In one embodiment, the patient is a mammal, and more specifically a human. As will be understood by one skilled in the art, the invention also encompasses methods of treating non-human patients such as companion animals, e.g., cats, dogs, and livestock animals.

[0197] A therapeutically effective amount of a pharmaceutical composition is preferably an amount sufficient to reduce or ameliorate the symptoms of a disease or condition. In the case of KRAS-mediated diseases for example, a therapeutically effective amount may be an amount sufficient to reduce or ameliorate cancer. A therapeutically effective amount of a compound or pharmaceutical composition described herein will also provide a sufficient concentration of a compound of Formula I when administered to a patient. A sufficient concentration is preferably a concentration of the compound in the patient’s body necessary to prevent or combat the disorder. Such an amount may be ascertained experimentally, for example by assaying blood concentration of the compound, or theoretically, by calculating bioavailability.

[0198] According to the invention, the methods of treatment disclosed herein include providing certain dosage amounts of a compound of Formula I to a patient. Dosage levels of each compound of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of compound that may be combined with the carrier materials to produce a single dosage form will vary depending upon the patient treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of each active compound. In certain embodiments 25 mg to 500 mg, or 25 mg to 200 mg of a compound of Formula I are provided daily to a patient.

[0199] Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most KRAS-mediated diseases and disorders, a dosage regimen of 4 times daily or less can be used and in certain embodiments a dosage regimen of 1 or 2 times daily is used.

[0200] It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route ofAttorney Docket No. BPR0115PCT

[0201] administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

[0202] A compound of Formula I may be administered singularly (i.e., sole therapeutic agent of a regime) to treat or prevent KRAS-mediated diseases and conditions such as various cancers or may be administered in combination with another active agent. One or more compounds of Formula I may be administered in coordination with a regime of one or more other active agents such as anticancer cytotoxic agents. In an embodiment, a method of treating or diagnosing KRAS-mediated cancer in a mammal includes administering to said mammal a therapeutically effective amount of a compound of Formula I, optionally in combination with one or more additional active ingredients.

[0203] As will be appreciated by one skilled in the art, the methods of treatment provided herein are also useful for treatment of mammals other than humans, including for veterinary applications such as to treat horses and livestock, e.g., cattle, sheep, cows, goats, swine and the like, and pets (companion animals) such as dogs and cats.

[0204] For diagnostic or research applications, a wide variety of mammals will be suitable subjects including rodents (e.g., mice, rats, hamsters), rabbits, primates, and swine such as inbred pigs and the like. Additionally, for in vitro applications, such as in vitro diagnostic and research applications, body fluids (e.g., blood, plasma, serum, cellular interstitial fluid, saliva, feces, and urine) and cell and tissue samples of the above subjects will be suitable for use.

[0205] In one embodiment, the invention provides a method of treating a disease, disorder, or medical condition mediated through KRAS, especially the KRAS mutants G12C and G12D, including various cancers, in a patient identified as in need of such treatment, the method comprising providing to the patient an effective amount of a compound of Formula I. The compounds of Formula I provided herein may be administered alone, or in combination with one or more other active agents.

[0206] In another embodiment, the method of treating or diagnosing KRAS-mediated diseases or conditions may additionally comprise administering the compound of Formula I in combination with one or more additional compounds, wherein at least one of the additional compounds is an active agent, to a patient in need of such treatment. The one or more additional compounds may include additional therapeutic compounds, including anticancer therapeutic compounds such as doxorubicin, paclitaxel, docetaxel, cisplatin, camptothecin, temozolomide, avastin, Herceptin, Erbitux, EGFR inhibitors, osimertinib, rezivertinib, CDK 4 / 6 inhibitors, abemaciclib, palbociclib, ribociclib, c-MET inhibitors, capmatinib, volitinib,Attorney Docket No. BPR0115PCT

[0207] ALK inhibitors, crizotinib, alectinib. ceritinib, brigatinib, entrectinib, lorlatinib, PD-1 antagonists, PD-L1 antagonists, ipilimumab, embrolizumab, nivolumab, and the like.

[0208] EXAMPLES

[0209] Abbreviations and Acronyms

[0210] The following abbreviations and acronyms may be used in this application:

[0211] anhyd. = anhydrous;

[0212] aq. = aqueous;

[0213] B₂pin₂ = bis(pinacolato)diboron;

[0214] Boc = tert-butoxycarbonyl;

[0215] n-Bu₃P = tri-n-butylphosphine;

[0216] Compd = compound;

[0217] d = day(s);

[0218] DCM = dichloromethane;

[0219] DIEA = DIPEA = N,N-diisopropylethylamine;

[0220] DMF = N,N-dimethylformamide;

[0221] DMSO = dimethylsulfoxide;

[0222] DMA = N,N-dimethylacetamide;

[0223] dppf = 1,1'-bis(diphenylphosphino)ferrocene);

[0224] DTBPF = 1,1'-bis(di-tert-butylphosphino)ferrocene;

[0225] EtOAc = ethyl acetate;

[0226] equiv = equivalents;

[0227] Ex = Example;

[0228] h = hour(s);

[0229] KOAc = potassium acetate;

[0230] LiHMDS = lithium bis(trimethylsilyl)amide [LiN(SiMe₃)₂];

[0231] mCPBA = meta-chloroperoxybenzoic acid:

[0232] MeOH = methanol;

[0233] NMP = N-methyl-2-pyrrolidone;

[0234] min = minutes;

[0235] Pd(dppf)Cl₂ = [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II);

[0236] RT = room temperature;

[0237] satd. = saturated solution;Attorney Docket No. BPR0115PCT

[0238] TEA = triethylamine;

[0239] TFA = trifluoroacetic acid:

[0240] THF = tetrahydrofuran;

[0241] The present inventive concept has been described in terms of exemplary principles and embodiments, but those skilled in the art will recognize that variations may be made and equivalents substituted for what is described without departing from the scope and spirit of the disclosure as defined by the following claims.

[0242] Chemical Synthesis

[0243] The compounds of the Formula I described herein, and / or the pharmaceutically acceptable salts thereof, can be synthesized from commercially available starting materials by methods well known to those skilled in the art of synthetic organic chemistry. The following general synthetic Schemes 1 and 2 illustrate representative methods to prepare most of the example compounds. In the specific examples where the Suzuki cross-coupling reaction of arylboronic acids / esters with organohalides / pseudohalides (Beketskaya, I. P. et al., Coordin. Chem. Rev. 2019, 385, 137-173) is either impractical or unsuccessful, then the corresponding Stille cross-coupling reaction of organostannanes with organohalides / pseudohalides may be used as an alternative (Espinet, P. et al., ACS Catal. 2015, 5, 3040-3053). Many of the requisite intermediates can be prepared as described in WO2021041671. The listed starting materials, reactions, reagents, solvents, temperatures, catalysts and ligands are not limited to what is depicted for purely illustrative purposes. Certain abbreviations and acronyms well known to those trained in the art that may be used in Schemes 1 and 2 as well as in the Examples are listed below for clarity.

[0244] The synthesis of compounds of this invention is exemplified by the sequence of steps shown in Scheme 1. In Scheme 1, oxidation of 1,5-naphthyridine derivative 3 with mCPBA in a solvent such as CH2CI2 generates A-oxide compound 4. Reaction of 4 with POCI3 at an elevated temperature furnishes the corresponding chloro derivative 5. Reaction of 5 with 6 yields compound 7. Treatment of 8 with an appropriate base such as sodium hydride, Hiinig’s base, K2CO3 or a CS2CO3 / DABCO mixture followed by reaction with 7 in a polar aprotic solvent such as A-methyl-2-pyrrolidone at RT or elevated temperature generates compound 9. Suzuki-Miyaura coupling of 9 with a boronic ester such as 10 (or the corresponding boronic acid) under standard conditions in solvent mixture such as 1,4-dioxane and water can be employed to prepare 11. Removal of the Boc protecting group of 11 under acidic conditions such as anhydrous 4M HC1 in 1,4-dioxane or TFA in CH2Q2 generatesAttorney Docket No. BPR0115PCT

[0245] compounds of Formula I where R2is hydrogen (12). Acylation of 12 with acryloyl chloride 13 in a solvent such as methylene chloride containing a base such as triethylamine, will produce the corresponding compounds 14 of the Formula I where R2is either -C(O)CH=CH, -C(O)CF=CH or -C(O)CC1=CH.

[0246] Scheme 1

[0247] mCPBA POCI3CH2CI2A 4

[0248] G

[0249] 4 M HCI Pd(PPh3)41,4-di oxane K2CO3CH2CI21,4-dioxane / H2O A

[0250] Et3N, CH2CI2(where R7is H, F or Cl)

[0251]

[0252] Attorney Docket No. BPR0115PCTAttorney Docket No. BPR0115PCT

[0253] Example 1

[0254] 2-((S)-l-Acryloyl-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (lb).

[0255]

[0256] lb

[0257] The compound of Example 1 (lb) was prepared as shown below in Scheme 2.Attorney Docket No. BPR0115PCT

[0258] Scheme 2

[0259] 22 Pd(PPh3)4K2CO31,4-dioxane / H20 80 °C

[0260] Et3N, CH2CI2

[0261]

[0262] 7-Bromo-4-chloro-l,5-naphthyridine-l-oxide (16). This compound was prepared as described on pages 64-65 in W02020150114 from the reaction of mCPBA and 3-bromo-8-chloro-l,5-naphthyridine (15; CAS # 97267-61-3; 1.70 g, 7.02 mmol) in CH2Q2 to afford 1.50 g (83%) of 7-bromo-4-chloro-l,5-naphthyridine-l-oxide (16) as a pale-yellow solid:

[0263] HPLC-MS (ES+) m / z [M+H+] = 259, 261, 263; ’H NMR (300 MHz, CDCb) 59.24 (d, J = 2.2 Hz, 1H), 9.12 (d, J= 2.2 Hz, 1H), 8.44 (d, J = 6.7 Hz, 1H), 7.63 (d, J= 6.7 Hz, 1H).Attorney Docket No. BPR0115PCT

[0264] 7-Bromo-2,4-dichloro-l,5-naphthyridine (17). This compound was prepared as described on page 65 in W02020150114 from 7-bromo-4-chloro-l,5-naphthyridine-l-oxide (16; 775 mg, 3.00 mmol) to afford 750 mg (90%) of 7-bromo-2,4-dichloro-l,5-naphthyridine (17)as a pink solid: HPLC-MS (ES+) m / z [M+H+] = 277, 279, 281, 283; ‘H NMR (300 MHz, CDC13) 89.05 (d, 7 = 2.1 Hz, 1H), 8.51 (d, 7 = 2.1 Hz, 1H), 7.78 (s. 1H).

[0265] te / 7-Bulyl (S)-4-(7-bromo-2-chloro-l,5-naphthyridin-4-yl)-2- (cyanomethyl)piperazine-l-carboxylate (19). Triethylamine (1.90 mL, 13.6 mmol) was added to a suspension of (5)-2-(piperazin-2-yl)acetonitrile dihydrochloride (18; CAS # 1589082-26-7; 538 mg, 2.72 mmol) in anhydrous 1,4-dioxane (10 mL) and stirred at RT. After 5 h, the mixture was cooled to 0°C and anhydrous 1,4-dioxane (20 mL) was added followed by the portionwise addition of 7-bromo-2,4-dichloro-l,5-naphthyridine (17; 750 mg, 2.72 mmol). After complete addition, the ice bath was removed, wanned to RT and after 5 minutes the reaction mixture was heated at reflux for 23 h. The mixture was cooled to RT and di-tert-butyl dicarbonate (1.87 mL, 8.16 mmol) was added. After 16 h, the mixture was diluted with EtOAc, washed with satd. aq. NaCl (3X), dried (MgSCU), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with a gradient of 10% to 40% EtOAc in hexane to afford 610 mg (48%) (the first eluting isomer) of tert-butyl (S)-4-(7-bromo-2-chloro-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (19) as a white solid: HPLC-MS (ES+) mJz [M+H+] = 466, 468, 470; ’H NMR (300 MHz, CDCI3) 88.89 (d, 7= 2.2 Hz, 1H), 8.37 (d, 7= 2.2 Hz, 1H), 6.83 (s, 1H), 4.94 (d, 7= 12.6 Hz, 1H), 4.63 (br s, 1H), 4.18 (br s, 1H), 3.76-3.68 (m, 1H), 3.33-3.06 (m, 4H), 2.79 (dd, 7= 5.3, 10.9 Hz, 1H), 1.53 (s, 9H).

[0266] t ert- Butyl (S)-4-(7-bromo-2-(((S)-l-methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l-carboxylate (21). A mixture of tertbutyl (S)-4-(7-bromo-2-chloro-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l-carboxylate (19; 390 mg, 0.839 mmol), (2S)-l-methyl-2-pyrrolidinemethanol (20; CAS # 34381-71-0; 1.0 mL, 8.0 mmol), and CS2CO3 (545 mg, 1.68 mmol) in anhydrous CH3CN (8 mL) was heated at reflux. After 72 h, the mixture was cooled to RT, diluted with EtOAc, washed with satd. aq. NaCl (3X), dried (MgSOA, filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with a gradient of 0% to 15% MeOH in DCM to afford 80 mg (17%) of tert-butyl (S)-4-(7-bromo-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-1,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate as a light brown solid: HPLC-MS (ES+) m / z [M+H+] = 545, 547; 'H NMR (300Attorney Docket No. BPR0115PCT

[0267] MHz, CDCh) 88.72 (d, J = 2.2 Hz, 1H), 8.22 (d, J = 2.2 Hz, 1H), 6.41 (s, 1H). 4.74 (d, J = 12.5 Hz, 1H), 4.62 (br s, 1H), 4.48 (dd, 7= 4.8, 6.4 Hz, 1H), 4.36 (dd, 7= 4.8, 6.4 Hz, 1H), 4.15 (br s, 1H), 3.60 (d, 7 = 5.8 Hz, 1H), 3.22 (br s, 1H), 3.32 (dd, 7 = 7.7, 8.8 Hz, 1H), 3.14 (t, 7 = 7.4 Hz, 1H). 2.98 (td, 7 = 3.3, 9.1 Hz, 2H), 2.83 (dd, 7 = 5.6, 10.7 Hz, 1H), 2.67-2.57 (m, 1H), 2.48 (s, 3H), 2.34-2.22 (m, 1H), 2.06-1.94 (m, 1H), 1.93-1.71 (m, 3H), 1.52 (s, 9H).

[0268] tert- Butyl (S)-4-(7-(8-chloronaphthalen-l -yl)-2-(((S)-l -methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l-carboxylate (23). A mixture of tert-butyl (> S')-4-(7-bromo-2-(((S)-l-methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (21; 106 mg, 0.195 mmol), 2-(8-chloronaphthalen-l-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (22; 225 mg, 0.780 mmol), and K2CO3 (487 mg, 3.53 mmol) in 1,4-dioxane (3 mL) and water (1.4 mL) was degassed by sparging with N2 with stirring for 30 minutes.

[0269] Tetrakis(triphenylphosphine)palladium(0) (33 mg, 0.029 mmol) was added and the reaction mixture degassed by sparging with N2 with stirring for an additional 20 minutes. The reaction mixture was heated at 80°C with stirring under a N2 atmosphere for 16 h. The reaction mixture was cooled to RT, diluted with EtOAc, filtered through Celite and the filtrate was then washed with satd. aq. NaCl (3X), dried (MgSC ), filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with a gradient of 0% to 10% MeOH in DCM to afford 48 mg (39%) of tert-butyl (5)-4-(7-(8-chloronaphthalen-1 -yl)-2-(((S)-l -methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (23) as an off-white solid: HPLC-MS (ES+) m / z [M+H+] = 627, 629;1H NMR (300 MHz, CDCh) 88.67 (d, 7 = 2.1 Hz, 1H), 8.02 (t, 7 = 2.0 Hz, 1H), 7.94 (d, 7 = 7.8 Hz, 1H), 7.87 (d, 7 = 7.5 Hz, 1H), 7.55 (t, 7 = 7.8 Hz, 2H), 7.42 (t, 7 = 7.4 Hz, 2H), 6.45 (d, 7= 2.5 Hz, 1H), 4.92 (d, 7= 11.6 Hz, 1H), 4.79 (d, 7= 13.8 Hz, 1H), 4.67 (br s, 1H), 4.58-4.48 (m, 1H), 4.44-4.35 (m, 1H), 4.20 (br s, 1H), 3.70 (br t, 7= 10.3 Hz, 1H), 3.46-3.21 (m, 2H), 3.19-2.88 (m, 4H), 2.63 (br s, 1H), 2.49 (s, 3H), 2.34-2.22 (m, 1H), 2.08-1.69 (m, 3H), 1.53 (s, 9H).

[0270] 2-((S)-4-(7-(8-Chloronaphthalen-l-yl)-2-(((S)-l-methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (24). A solution of tert-butyl (5)-4-(7-(8-chloronaphthalen-1 -yl)-2-(((S)-l -methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (23; 44 mg, 0.070 mmol) in CH2CI2 (2 mL) was treated with a solution of 4 M HCl / l,4-dioxane (0.2 mL) and stirred at RT. After 16 h, the mixture was treated with 0.1 M NaOH solution until the pH was basic. The layers wereAttorney Docket No. BPR0115PCT

[0271] separated and the aqueous layer was extracted with CH2Q2 (3X), dried (MgSCU), filtered, and concentrated in vacuo to afford 31 mg (84%) of 2-((5)-4-(7-(8-chloronaphthalen-l-yl)-2-(((5)-l-methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (24) as an off-white solid: HPLC-MS (ES+) mJz [M+H+] = 527, 529; 'H NMR (300 MHz, CDCI3) 88.64 (ddd, 7 = 1.4, 2.2, 2.8 Hz, 1H), 8.04-7.99 (m, 1H), 7.95 (dd, 7 = 1.2, 7.0 Hz, 1H), 7.88 (dd, J = 1.2, 7.0 Hz, 1H), 7.62-7.49 (m, 2H), 7.47-7.37 (m, 2H), 6.46 (s, 1H), 4.59-4.47 (m, 1H), 4.44-4.32 (m, 1H), 4.29-3.84 (m, 2H), 3.80-3.73 (m, 1H), 3.68-3.60 (m, 1H), 3.57-3.44 (m, 1H), 3.32-2.84 (m, 4H), 2.74-2.56 (m, 2H), 2.49 (s, 3H), 2.43-2.20 (m, 2H), 2.10-1.47 (m, 4H).

[0272] 2-((S)-l-Acryloyl-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (lb). A solution of 2-((S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (24; 50 mg, 0.095 mmol) in CH2Q2 (8 mL) was treated with EtsN (16 pL, 0.114 mmol) and stirred at RT. The mixture was cooled to 0°C and treated with acryloyl chloride (25; CAS # 814-68-6; 10 pL, 0.114 mmol). After 1 h at 0°C, the mixture was diluted with CH2Q2 and washed with H2O (2X). The layers were separated and the CH2Q2 layer was dried (MgSCU), filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with a gradient of 0% to 10% MeOH in DCM containing 5% NH4OH (v / v) to afford 20 mg (36%) of 2-((S)-l-acryloyl-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-methylpyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (lb) as an off-white solid: HPLC-MS (ES+) m / z [M+H+] = 581, 583; ’H NMR (300 MHz, CDCI3) 88.69 (bs, 1H), 8.04 (t, 7 = 2.1 Hz, 1H), 7.96 (d, 7 = 8.3 Hz, 1H), 7.89 (d, 7 = 8.0 Hz, 1H), 7.62-7.55 (m, 2H), 7.47-7.38 (m, 2H), 6.65 (bs, 1H), 6.46 (d, 7= 2.8 Hz, 1H), 6.40 (dd, 7= 1.7, 18.2 Hz, 1H), 5.82 (d, 7= 10.5 Hz, 1H), 4.61-4.48 (m, 1H), 4.46-4.34 (m, 1H), 4.16-3.29 (m, 4H), 3.25-2.88 (m, 5H), 2.63 (bs, 1H), 2.49 (s, 3H), 2.39-2.18 (m, 1H), 2.10-1.68 (m, 5H).Attorney Docket No. BPR0115PCT

[0273] Example 2

[0274] (2S,4R)-l-((S)-2-(3-(3-((S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-l-yl)-7-(8-chloronaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

[0275]

[0276] The compound of Example 2 (2b) was prepared as shown below in Scheme 4.Attorney Docket No. BPR0115PCT NaH THF

[0277] TFA

[0278] Pd(PPh3)4CH2CI2K2CO3dioxane / H2O

[0279]

[0280] Methyl 3-(3-iodopropoxy)propanoate (27). Methyl 3-(3-iodopropoxy)propanoate (27) was produced as shown in Scheme 3.Attorney Docket No. BPR0115PCT

[0281] Scheme 3

[0282] PPh3

[0283] imidazole

[0284] h

[0285]

[0286] CH2CI227 As shown in Scheme 3, a solution of methyl 3-(3-hydroxypropoxy)propanoate (26, CAS #: 2169516-61-2; 1.0 g, 6.16 mmol) in anhydrous DCM (20 mL) was treated with PPh₃ (1.78 g, 6.78 mmol) and imidazole (503 mg, 7.39 mmol). Iodine (1.72 g, 6.78 mmol) was added slowly portionwise and the mixture stirred at RT. After 16 h, an aqueous solution of satd. sodium thiosulfate pentahydrate was added and the mixture stirred at RT. After 10 min, the layers were separated and the aqueous layer extracted with DCM (3X). The layers were combined, dried (MgSC ), filtered, and concentrated in vacuo. Hexane was added to the erode residue and the insoluble triphenylphosphine oxide was filtered. The filtrate was concentrated in vacuo to a yellow oil. The crude product was purified by silica gel column chromatography eluting with gradient of 1% to 10% EtOAc / hexane to afford 1.0 g (60%) of methyl 3-(3-iodopropoxy)propanoate (27) as a colorless oil: HRMS HPLC-MS (ES+) m / z [M+H+] ealed for C7H13IO3, 272.9988; found, 272.9993; 'H NMR (300 MHz, CDCI3) 83.77 - 3.67 (m, 5H), 3.51 (t,. / = 5.8 Hz, 2H), 3.26 (t,. / = 6.7 Hz, 2H), 2.59 (t,. / = 6.3 Hz, 2H), 2.11 - 1.97 (m, 2H).

[0287] tert-butyl (S)-4-(7-bromo-2-(((S)-pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l-carboxylate (29). Sodium hydride (174 mg, 4.26 mmol, 60% w / w dispersion in mineral oil) was added to a solution of (S)-(+)-2-pyrrolidinemethanol (28; CAS # 23356-96-9; 440 mg, 4.26 mmol) in anhydrous THF (25 mL) at 0°C under aN2 atmosphere. After 1 h, tert-butyl (S)-4-(7-bromo-2-chloro-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l-carboxylate (19; 1.32 g, 2.84 mmol) was added portionwise and the mixture heated at 60°C. After 16 h, the mixture was cooled to RT, satd. aq. NH4CI was added and stirred. After 5 min, the mixture was extracted with EtOAc (3X), washed with satd. aq. NaCl (2X), dried (MgSCL), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with gradient of 0% to 15% MeOH in DCM containing 5% NH4OH (v / v) to afford 795 mg (53%) of tert-butyl (S)-4-(7-bromo-2-(((S)-pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l-carboxylate (29) as an off-white foam; HRMS HPLC-MS (ES+) m / z: [M+H+] ealed forAttorney Docket No. BPR0115PCT

[0288] C₂₄H₃₁BrN₆O₃, 531.1719; found, 531.1715; NMR (300 MHz, DMSO-d6) 58.69 (d, 7 = 2.3 Hz. 1H), 8.29 (d, J= 2.3 Hz, 1H), 6.45 (s, 1H), 4.49 (br d, J= 16.2 Hz, 2H), 4.28 - 4.11 (m, 2H), 3.96 (br d, J= 13.6 Hz, 1H), 3.77 (br d, J = 11.8 Hz, 1H), 3.40 (quint, J= 6.6 Hz, 1H), 3.28 (br s, 2H), 3.13 (d, 7 = 6.7 Hz, 2H), 2.96 (ddd, 7= 25.4, 12.3, 3.5 Hz, 2H), 2.87 -2.79 (m, 2H), 1.92 - 1.76 (m, 1H), 1.76 - 1.55 (m, 2H), 1.45 (s, 9H).

[0289] tert-butyl (S)-4-(7-bromo-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l-carboxylate (30). Triethylamine (0.4 mL, 2.89 mmol) was added to a solution of tert-butyl (S)-4-(7-bromo-2-(((S)-pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (29; 510 mg, 0.964 mmol) and methyl 3-(3-iodopropoxy)propanoate (27; 262 mg, 0.964 mmol) in anhydrous DMF (2 mL) and the mixture stirred at RT. After 16 h, the mixture was diluted with EtOAc, washed with satd. aq. NaCl (4X), dried (MgSCU), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with gradient of 0% to 10% MeOH in DCM to afford 491 mg (53%) of tert-butyl (S)-4-(7-bromo-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (30) as an amber oil: HRMS HPLC-MS (ES+) m / z [M+H+] calcd for C₃₁H₄₅BrN₆O₆, 675.2506; found, 675.2514; ’H NMR (300 MHz, DMSO-d6) 58.71 (d, 7= 2.2 Hz, 1H), 8.30 (d, 7= 2.3 Hz, 1H), 6.45 (s, 1H), 4.53 (br s, 1H), 4.38 (dd, 7 = 10.8, 4.5 Hz, 1H), 4.12 (dd, 7 = 10.8, 6.9 Hz, 2H), 3.96 (br d, 7 = 13.4 Hz, 1H), 3.79 (br d, 7= 11.7 Hz, 1H), 3.58 - 3.54 (m, 5H), 3.33 (br s, 2H), 3.41 (t, 7= 6.4 Hz, 2H), 3.27 - 2.84 (m, 5H), 2.78 (br s, 1H), 2.40 - 2.26 (m, 2H), 2.22 - 2.09 (m, 3H), 1.91 (dd, 7= 10.7, 6.6 Hz, 1H), 1.76 - 1.57 (m, 4H), 1.46 (s, 9H).

[0290] tert-butyl (S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2- (cyanomethyl)piperazine-l-carboxylate (31). A mixture of tert-butyl (S)-4-(7-bromo-2-(((S)-1-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (30; 470 mg, 0.696 mmol), 2-(8-chloronaphthalen-l-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (22; CAS #: 2454397-84-1; 400 mg, 1.39 mmol), and K2CO3 (384 mg, 2.78 mmol) in dioxane (7 mL) and water (1.4 mL) was degassed by sparging with N2 with stirring for 20 minutes.

[0291] Tetrakis(triphenylphosphine)palladium (0) (80 mg, 0.070 mmol) was added and the reaction mixture degassed by sparging with N2 with stirring for an additional 15 minutes. The reactionAttorney Docket No. BPR0115PCT

[0292] mixture was heated at 85°C while stirring under a N2 atmosphere for 16 h. After 16 h, the mixture was heated at 95°C for an additional 48 h. The reaction mixture was cooled to RT, diluted with EtOAc, washed with satd. aq. NaCl (2X), dried (MgSCU), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluting with a gradient of 0% to 10% MeOH in DCM containing 5% NH4OH (v / v) to afford 216 mg (41%) of tert-butyl (S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (31) as a colorless oil: HRMS HPLC-MS (ES+) m / z:

[0293] [M+H+] calcd for C41H49CIN6O6, 757.3480; found, 757.3495.

[0294] Methyl 3-(3-((S)-2-(((7-(8-chloronaphthalen-l-yl)-4-((S)-3-(cyanomethyl)piperazin-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoate (32). A solution of tert-butyl (S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (31; 216 mg, 0.285 mmol) in anhydrous DCM (13 mL) was treated with TFA (1.3 mL) slowly dropwise and the mixture stirred at RT. After 2 h, the mixture was added to satd. aq. NaHCCE via pipette, extracted with DCM (3X), dried (MgSCh), filtered, and concentrated in vacuo to afford 148 mg (79%) of methyl 3-(3-((S)-2-(((7-(8-chloronaphthalen-l-yl)-4-((S)-3-(cyanomethyl)piperazin-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoate (32): HRMS HPLC-MS (ES+) m / z [M+H+] calcd for C36H41CIN6O4, 657.2956; found, 657.2959.

[0295] 3-(3-((S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-l-yl)-7-(8-chloronaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoic acid (35). A solution of methyl 3-(3-((S)-2-(((7-(8-chloronaphthalen-1 -yl)-4-((S)-3-(cyanomethyl)piperazin- 1 -yl)- 1,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l -yl)propoxy)propanoate (32; 118 mg, 0.18 mmol) and N-methylmorpholine (34; CAS # 109-02-4; 31 iiL. 0.28 mmol) in anhydrous THF (6 mL) was treated with 3-chloropropionyl chloride (33; CAS # 625-36-5; 25.8 pL, 0.27 mmol) and the mixture stirred at RT under aN2 atmosphere. The initial clear solution became cloudy after 10 min. After 1 h, an aqueous NaOH solution (0.62 mL, 3.56 mmol, 5.75 M) was added resulting in a clear solution and the mixture stirred at 50°C under a N2 atmosphere. After 3 h, additional anhydrous THF (6 mL) was added and the mixture stirred at 50°C under a N2 atmosphere. After 16 h, the mixture was cooled to RT then cooled to 0°C. An aqueous solution of 2 M HC1 was added slowly to attain a pH of about 5. The mixture was extracted with EtOAc (4X), dried (MgSO4), filtered,Attorney Docket No. BPR0115PCT

[0296] and concentrated in vacuo to afford 68 mg (54%) of 3-(3-((S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-l-yl)-7-(8-chloronaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoic acid (35) as a beige solid: HRMS HPLC-MS (ES+) m / z [M+H+] calcd for C3SH41CIN6O5, 657.2905; found, 657.2914; HRMS HPLC-MS (ES ) m / z: [M-H+] calcd for C38H41CIN6O5, 695.2749; found, 695.2768.

[0297] (2S,4R)-l-((S)-2-(3-(3-((S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-l-yl)-7-(8-chloronaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (2b). A solution of 3-(3-((S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-l-yl)-7-(8-chloronaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoic acid (35; 48 mg, 0.069 mmol). 1-hydroxybenzotriazole hydrate (CAS #: 123333-53-9; 21 mg, 0.138 mmol), and (2S,4R)-1-((S)-2-ammo-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (36; CAS #: 1448297-52-6; 45 mg, 0.103 mmol) in anhydrous DMF (1.8 mb) was treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (CAS #: 25952-53-8; 33 mg, 0.172 mmol) and triethylamine (50 pL, 0.345 mmol) and the mixture stirred at RT under a N2 atmosphere After 16 h, the mixture was diluted with EtOAc, washed with H2O (4X), satd. aq. NaHCCh (3X), dried (MgSCh), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluting with a gradient of 0% to 10% MeOH in DCM then 5% to 10% MeOH in DCM containing 5% NH4OH (v / v) to afford 18.4 mg (24%) of (2S,4R)-l-((S)-2-(3-(3-((S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-l-yl)-7-(8-chloronaphthalen-l-yl)- I,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (2b) as a white solid: HRMS HPLC-MS (ES+) m / z: [M+H+] calcd for C60H70CIN10O7S, 1109.4838; found, 1109.4872; ‘H NMR (300 MHz, CDCI3) 58.68 (br s, 1H), 8.66 (d, J= 2.2 Hz, 1H), 8.02 (d, J = 2.1 Hz, 1H), 7.96 (d, 7= 8.1 Hz, 1H), 7.89 (d, 7= 8.1 Hz, 1H), 7.64 -7.50 (m, 3H), 7.47 - 7.38 (m, 2H), 7.32 (br d, 7 = 1.5 Hz, 4H), 7.11 (br s, 1H), 6.64 (br s, 1H), 6.47 - 6.33 (m, 2H), 5.82 (d, 7 = 10.4 Hz, 1H), 5.23 (br s, 1H), 4.68 (q, 7 = 7.6 Hz, 1H), 4.57 (dd, 7 = 15.0, 6.6 Hz, 1 H), 4.42 (d, 7 = 8.1 Hz, 2H), 4.37 - 4.24 (m, 2H), 4.07 (d, 7 = II.2 Hz, 1H), 3.95 (br s, 1H), 3.62 - 3.57 (m, 2H), 3.54 (t, J= 4.6 Hz, 4H), 3.18 (br s, 1H), 3.13 - 2.94 (m, 6H), 2.81 (br s, 1H), 2.50 (d, 7= 1.2 Hz, 3H), 2.47 - 2.33 (m. 4H), 2.22 (br s, 2H), 2.12 - 1.43 (m, 10H), 0.91 (s, 9H).Attorney Docket No. BPR0115PCT

[0298] Example 3

[0299] 2-((2S)-l-acryloyl-4-(7-(8-chloronaphthalen-l-yl)-2-(((2S)-l-(3-(3-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)aceto nitrile

[0300]

[0301] 3b

[0302] The compound shown in Example 3 (3b) can be prepared according to the synthetic method described in Scheme 5.Attorney Docket No. BPR0115PCT

[0303] Scheme 5

[0304]

[0305] Attorney Docket No. BPR0115PCT

[0306]

[0307] 3b

[0308] 3-(3-((S)-2-(((4-((S)-4-(tert-butoxycarbonyl)-3-(cyanomethyl)piperazin-l-yl)-7-(8-chloronaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoic acid (37). Lithium hydroxide (77 mg, 3.18 mmol) was added to a mixture of tert-butyl (S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (31; 230 mg, 0.303 mmol) inTHF (1.9 mL), MeOH (1.9 mL), and water (0.64 mL) and the mixture stirred at RT. After 16 h, the mixture was diluted with water and the pH of the mixture adjusted to pH = 5 with 1 M HC1 solution. The mixture was extracted with EtOAc (4X), dried (MgSCU), filtered, and concentrated in vacuo to afford 181 mg (80%) of 3-(3-((S)-2-(((4-((S)-4-(tert-butoxycarbonyl)-3-(cyanomethyl)piperazin- 1 -yl)-7 -(8-chloronaphthalen- 1 -y 1) - 1,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoic acid (37) as a pale yellow solid: HRMS HPLC-MS (ES+) m / z- [M+H+] calcd for C₄₀H₄₅ClN₆O₆, 743.3324; found, 743.3317.Attorney Docket No. BPR0115PCT

[0309] tert-butyl (S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l-carboxylate (39). A mixture of 3-(3-((S)-2-(((4-((S)-4-(tert-butoxycarbonyl)-3-(cyanomethyl)piperazin-l-yl)-7-(8-chloronaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoic acid ( (37; 181 mg, 0.244 mmol). 1 -hydroxybenzotriazole hydrate (CAS #: 123333-53-9; 114 mg, 0.744 mmol), and (S)-3-(1-oxo-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione dihydrochloride (54; CAS #: 50533-97-6; 182 mg, 0.366 mmol) in anhydrous DMF (2.4 mL) was treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (CAS #: 25952-53-8; 122 mg, 0.647 mmol) and triethylamine (0.2 mL, 1.46 mmol) and the mixture stirred at RT under a N2 atmosphere for 16 h. After 16 h, the mixture was diluted with EtOAc, washed with satd. aq. NaCl (4X), dried (MgSCU), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluting with a gradient of 0% to 15% MeOH in DCM containing 5% NH4OH (v / v) to afford 206 mg (74%) of te / 7-butyl (S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5 -yl)piperazin- 1 -yl)methyl)piperidin- 1 -yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (39) as an off-white solid; HRMS HPLC-MS (ES+) m / z [M+H+] calcd for C63H77CIN11O8, 1150.5645; found, 1150.5669.

[0310] 2-((S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (40). A solution of te / 7-butyl (S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperi din-1 -yl)-3-oxopropoxy)propyl)pyrroli din-2-yl)methoxy)-l, 5-naphthyridin-4-yl)-2-(cyanomethyl)piperazine-l -carboxylate (39; 149 mg, 0.129 mmol) in a mixture of TFA (0.64 mL) and anhydrous DCM (6.4 mL) was stirred at RT. After 1.5 h, the mixture was pipetted into sat. aq. NaHCCh, extracted with DCM (4X), dried (MgSCU), filtered, and concentrated in vacuo to afford 109 mg (80%) of 2-((S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperi din-1 -yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l, 5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (40) as a tan solid; HRMS HPLC-MS (ES+) m / z [M+H+] calcd for C58H69CIN11O6, 1050.5121; found, 1050.5132.Attorney Docket No. BPR0115PCT

[0311] 2-((S)-l-acryloyl-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (3b). A solution of2-((S)-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl) acetonitrile (40; 89 mg, 0.085 mmol) in anhydrous DCM (4.2 mL) was treated with EtaN (0.5 mL, 0.102 mmol, 0.2 M in DCM) and stirred at RT. The mixture was cooled to 0°C and treated with acryloyl chloride (25; CAS # 814-68-6; 0.5 mL, 0.102 mmol, 0.2 M in DCM). After 1 h at 0°C, the mixture was diluted with DCM, washed with H2O (3X), dried (MgSCU), filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with a gradient of 0% to 10% MeOH in DCM containing 5% NH4OH (v / v) to afford 54.8 mg (59%) of 2-((S)-l-acryloyl-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (3b) as an off-white solid: HRMS HPLC-MS (ES+) m / z [M+H+] calcd for C61H71CIN11O7, 1104.5226; found, 1104.5221; ‘H NMR (300 MHz, DMSO-de) 810.9 (s, 1H), 8.61 (brs, 1H), 8.13 (d, J = 8.2 Hz, 1H), 8.10 (dd, 7 = 7.1, 1.1 Hz, 1H), 8.02 - 7.95 (m, 1H), 7.74-7.62 (m, 2H), 7.57 (t, J = 7.7 Hz, 2H), 7.51 (d, J= 9.2 Hz, 1H), 7.07 - 6.81 (m, 3H), 6.47 (d, J= 5.0 Hz, 1H), 6.20 (dd, J= 16.5, 1.8 Hz, 1H), 5.78 (dd, J= 10.3, 1.8 Hz, 1H), 5.05 (dd, 7= 13.2, 4.9 Hz, 2H), 4.90 - 4.60 (m, 2H), 4.59 - 4.04 (m, 6H), 3.92 (br s, 1H), 3.72 (br d, 7 = 11.2 Hz, 1H), 3.54 - 3.36 (m, 4H), 3.21 (br s, 5H), 3.10 - 2.54 (m, 9H), 2.46 - 2.24 (m, 9H). 2.22 - 1.84 (m, 6H), 1.78 - 1.52 (m, 9H).

[0312] Example 4

[0313] (S)-3-(5-(4-((l-(3-(3-((S)-2-(((4-((lR,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl- 7-fluoro-3-hydroxynaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoyl)piperidin-4-yl)methyl)piperazin-l-yl)-l-oxoisoindolin-2-yl)piperidine-2, 6-dioneAttorney Docket No. BPR0115PCT

[0314]

[0315] 4b

[0316] The compound shown in Example 4 (4b) can be prepared according to the synthetic method described in Scheme 6.Attorney Docket No. BPR0115PCT

[0317]

[0318] Attorney Docket No. BPR0115PCT

[0319]

[0320] Attorney Docket No. BPR0115PCT

[0321]

[0322] tert-butyl (lR,5S)-3-(7-bromo-2-chloro-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (42). Anhydrous triethylamine (3.40 mL, 24.5 mmol) was added to a suspension of 7-bromo-2,4-dichloro-l,5-naphthyridine (17; 2.25 g, 8.15 mmol) and tert-butyl (lR,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (41; CAS # 149771-44-8; 2.08 g, 9.78 mmol) in anhydrous 1,4-dioxane (37 mL) and the mixture heated at reflux. After 16 h, the mixture was cooled to RT, diluted with EtOAc, washed with satd. aq. NaCl (3X), dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with a gradient of 0% to 10% EtOAc / DCM to afford 1.51 g (41%) (the first eluting isomer) of tert-butyl (lR,5S)-3-(7-bromo-2-chloro-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (42) as a white solid: HRMS HPLC-MS (ES+) m / z [M+H+] calcd. for C17H22BrClN4O2, 453.0693;Attorney Docket No. BPR0115PCT

[0323] found, 453.0691; ‘H NMR (300 MHz, CDCh) 88.75 (d, J = 2.2 Hz, 1H), 8.33 (d, J= 2.2 Hz, 1H), 6.71 (s, 1H), 4.38 (br s, 4H), 3.23 (br s, 2H), 2.16 - 1.94 (m, 4H), 1.49 (s, 9H).

[0324] tert-butyl (lR,5S)-3-(7-bromo-2-(((S)-pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (43). Sodium hydride (266 mg, 6.66 mmol, 60% in mineral oil) was added to a solution of (S)-(+)-2-pyrrolidinemethanol (28; CAS # 23356-96-9; 0.66 mL, 6.66 mmol) in anhydrous THF (15 mL) cooled to 0°C and the mixture stirred at 0°C under a N2 atmosphere. After 1 h, tert-butyl (lR,5S)-3-(7-bromo-2-chloro-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (42; 1.51 g, 3.33 mmol) was added portion wise followed by rinsing of the flask with anhydrous THF (15 mL) and addition to the mixture at 0°C under a N2 atmosphere. The cooling bath was removed and the mixture heated at reflux. After 16 h, the mixture was diluted with EtOAc, washed with water (2X), satd. aq. NaCl (2X), dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with gradient of 0% to 12% MeOH in DCM containing 5% NH4OH (v / v) to afford 1.03 g (60%) of tert-butyl (lR,5S)-3-(7-bromo-2-(((S)-pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (43) as an off-white solid: HRMS HPLC-MS (ES+) m / z: [M+H+] calcd. for C24H33BrN5O3, 518.1767; found, 518.1774; ‘H NMR (300 MHz, DMSO-de) 88.70 (d, J = 2.2 Hz, 1H), 8.26 (d, J = 2.2 Hz, 1H), 6.36 (s, 1H), 4.33 - 4.11 (m, 6H), 3.40 (quint, J= 6.8 Hz, 1H), 3.01 (d, 7= 10.7 Hz, 2H), 2.90 - 2.73 (m, 3H), 2.10 - 1.54 (m, 8H), 1.44 (s, 9H).

[0325] tert-butyl (lR,5S)-3-(7-bromo-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (44). Anhydrous triethylamine (0.83 mL, 5.97 mmol) was added to a solution of tert-butyl (lR,5S)-3-(7-bromo-2-(((S)-pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (43; 1.03 g, 1.99 mmol) and methyl 3-(3-iodopropoxy)propanoate (27; 650 mg, 2.39 mmol) in anhydrous DMF (3.8 mL) and the mixture stirred at RT. After 16 h, the mixture was diluted with EtOAc, washed with satd. aq. NaCl (4X), dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with gradient of 0% to 10% MeOH in DCM to afford 847 mg (64%) of tert-butyl (lR,5S)-3-(7-bromo-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (44) as an amber oil: HRMS HPLC-MS (ES+) m / z [M+H+] calcd. for C31H49BrN5O6, 662.2553; found, 662.2561; ’H NMR (300 MHz, CDCh) 8Attorney Docket No. BPR0115PCT

[0326] 8.60 (d, J = 2.2 Hz, 1H), 8.19 (d, J = 2.3 Hz, 1H), 6.26 (s, 1H), 4.44 (dd, 7 = 10.8, 4.4 Hz, 1H), 4.36 (br s, 2H), 4.21 (dd, J = 9.9, 6.5 Hz. 2H), 3.70 (dd, J= 6.6, 0.8 Hz, 1H), 3.67(s, 3H), 3.51 (t, J = 6.6 Hz, 2H), 3.23 - 2.89 (m, 4H), 2.88 - 2.76 (m, 1H), 2.57 (t, J = 6.4 Hz, 2H), 2.48 - 2.35 (m, 1H), 2.30 - 2.09 (m, 4H), 2.02 - 1.93 (m, 4H), 1.87 - 1.68 (m, 5H), 1.49 (s, 9H).

[0327] tert-butyl (lR,5S)-3-(7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-l-yl)-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (46). A mixture of tert-butyl (lR,5S)-3-(7-bromo-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (44; 822 mg, 1.24 mmol), CataCXium A (CAS #: 321921-71-5; 89 mg, 0.250 mmol), ((2-fluoro-6-(methoxymethoxy)-8-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-l -yl)ethynyl)triisopropylsilane (45; CAS #: 2621932-37-2; 763 mg, 1.49 mmol), and K2CO3 (342 mg, 2.48 mmol) in toluene (7.4 mL) and water (1.4 mL) was degassed by sparging with N2 with stirring for 20 minutes.

[0328] CataCXium A Pd G2 (CAS #: 1375477-29-4; 83 mg, 0.120 mmol) was added and the reaction mixture degassed by sparging with N2 while stirring for an additional 20 minutes. The reaction mixture was heated at 100°C while stirring under a N2 atmosphere for 16 h. After 16 h, the reaction mixture was cooled to RT, diluted with EtOAc, washed with satd. aq. NaCl (3X), dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluting with a gradient of 0% to 10% MeOH in EtOAc to afford 938 mg (78%) of tert-butyl (lR,5S)-3-(7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-l-yl)-2-(((S)-l-(3-(3-methoxy-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (46) as an amber oil: HRMS HPLC-MS (ES+) m / z:

[0329] [M+H+] calcd. for C58H85FN5O8Si, 968.5369; found, 968.5366; ‘H NMR (300 MHz, CDCh) 58.66 (d, J = 2.2 Hz, 1H), 8.03 (dd, J = 2.2, 0.7 Hz, 1H), 7.78 (dd, J = 9.0, 5.7 Hz, 1H), 7.46 (d, 7= 2.6 Hz, 1H), 7.31 (t, 7= 8.7 Hz, 1H), 7.16 (d, 7 = 2.6 Hz, 1H), 6.28 (s, 1H), 5.30 (s, 2H), 4.47 (dt, 7 = 10.8. 4.2 Hz, 2H), 4.36 (br s, 1H), 4.21 (ddd, 7 = 10.8, 6.7, 5.4 Hz, 2H), 3.70 - 3.65 (m, 2H), 3.64 (d, 7= 1.6 Hz, 3H), 3.57 - 3.42 (m, 6H), 3.17 (dd, 7 = 8.3, 5.6 Hz.

[0330] 2H), 3.04 - 2.76 (m, 2H), 2.54 (td, 7= 6.5, 2.7 Hz, 2H), 2.41 (dt, 7= 12.0, 7.0 Hz, 1H), 2.24 (q, J = 8.5 Hz, 2H), 2.14 - 1.91 (m, 4H), 1.90 - 1.67 (m, 6H), 1.50 (s, 9H), 0.83 (d, 7 = 7.4 Hz, 9H), 0.79 (d, 7 = 7.4 Hz, 9H), 0.53 (ddq, 7= 11.3, 7.4, 3.7 Hz, 3H).Attorney Docket No. BPR0115PCT

[0331] 3-(3-((S)-2-(((4-((lR,5S)-8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoic acid (47). Lithium hydroxide (130 mg, 5.46 mmol) was added to a mixture of tert-butyl (lR,5S)-3-(7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-l-yl)-2-(((S)-l-(3-(3-methoxy-3 -oxopropoxy )propy l)py rrolidin-2-y 1) methoxy) -1,5 -naphthyridin-4-y 1) -3,8-diazabicyclo[3.2.1]octane-8-carboxylate (46; 500 mg. 0.520 mmol) in THF (3.3 mL), MeOH (3.3 mL), and water (1.1 mL) and the mixture stirred at RT. After 16 h, the mixture was diluted with water and the pH of the mixture adjusted to pH = 5-6 with 1 M HC1 solution. The mixture was extracted with EtOAc (3X), dried (MgSO4), filtered, and concentrated in vacuo to afford 441 mg (90%) of 3-(3-((S)-2-(((4-((lR,5S)-8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(7-fhioro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-l -yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l -yl)propoxy)propanoic acid (47) as an off-white foam: HRMS HPLC-MS (ES+) m / z [M+H+] calcd. for C53H73FN5O8Si, 954.5212; found, 954.5218.

[0332] tert- butyl (lR,5S)-3-(2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-l-yl)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (48). A mixture of 3-(3-((S)-2-(((4-((lR,5S)-8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen- 1 -yl) - 1,5 -naphthyridin-2-yl)oxy)methyl)pyrrolidin- 1 -yl)propoxy)propanoic acid (47; 417 mg, 0.437 mmol), 1 -hydroxybenzotriazole hydrate (CAS #: 123333-53-9; 212 mg, 1.38 mmol), and (S)-3-(1-oxo-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione dihydrochloride (54; 327 mg, 0.656 mmol) in anhydrous DMF (4.4 mL) was treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (CAS #: 25952-53-8; 226 mg, 1.18 mmol) and anhydrous triethylamine (0.36 mL, 2.62 mmol) and the mixture stirred at RT under a N2 atmosphere for 16 h. After 16 h, the mixture was diluted with EtOAc, washed with water (3X), satd. aq. NaCl (2X). dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluting with a gradient of 0% to 10% MeOH in DCM containing 1% Et3N (v / v) to afford 321 mg (54%) to afford of tert-butyl (lR,5S)-3-(2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-7-(7-fluoro-3-(methoxymethoxy)-8-Attorney Docket No. BPR0115PCT

[0333] ((triisopropylsilyl)ethynyl)naphthalen-l-yl)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (48) as an off-white solid: HRMS HPLC-MS (ES+) m / z [M+H+] calcd. for C76H102FN10O10Si, 1361.7534; found, 1361.7537; ‘H NMR (300 MHz, CDC13) 58.66 (d, J = 2.1 Hz, 1H), 8.15 (br s, 1H), 8.03 (t, J = 2.2 Hz, 1H), 7.84-7.68 (m, 2H), 7.46 (d, J = 2.6 Hz, 1H), 7.31 (d, J = 2.2 Hz, 1H), 7.16 (d, J = 2.6 Hz, 1H), 6.97 (d, 7= 8.7 Hz, 1H), 6.86 (s, 1H), 6.28 (d, J= 1.1 Hz, 1H), 5.29 (s, 2H), 5.20 (dd, J = 13.1, 5.2 Hz, 1H), 4.59 (brd, J= 13.1 Hz, 1H), 4.40 (d, J= 14.3 Hz, 2H), 4.38 (brs, 1H), 4.34 (brs, 1 H), 4.25 (d, J = 15.8 Hz, 2H), 3.86 (d, J = 13.6 Hz, 1 H), 3.76 - 3.64 (m, 2H), 3.55 - 3.45 (m, 2H), 3.51 (s, 3H), 3.27 (d, J = 5.8 Hz, 4H), 3.19 (br s, 1H), 2.99 - 2.85 (m, 4H), 2.83 (d, J = 5.5 Hz, 1H), 2.62 - 2.51 (m, 7H), 2.38 - 2.14 (m, 8H), 2.05 - 1.93 (m, 4H), 1.91 - 1.65 (m, 10H), 1.50 (s, 9H), 1.16 - 0.99 (m, 3H), 0.84 (d, J = 7.4 Hz, 9H), 0.78 (d, 7 = 7.4 Hz, 9H), 0.53 (ddq, 7= 11.3, 7.5, 3.7 Hz, 3H).

[0334] (S)-3-(5-(4-((l-(3-(3-((S)-2-(((4-((lR,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(7-fluoro-3-hydroxy-8-((triisopropylsilyl)ethynyl)naphthalen-l-yl)-l,5-naphthyri din-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoyl)piperidin-4-yl)methyl)piperazin-l-yl)-l-oxoisoindolin-2-yl)piperidine-2, 6-dione (49). A solution of tert-butyl (lR,5S)-3-(2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidin-l-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-l-yl)-l,5-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (48; 188 mg, 0.14 mmol) in a mixture of TFA (0.7 mL) and anhydrous DCM (7 mL) was stirred at RT. After 5 h, the mixture was pipetted into sat. aq. NaHCCh. extracted with DCM (3X), dried (MgSO4), filtered, and concentrated in vacuo to afford 133 mg (79%) of (S)-3-(5-(4-((l-(3-(3-((S)-2-(((4-((lR,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(7-fluoro-3-hydroxy-8-((triisopropylsilyl)ethynyl)naphthalen- 1 -yl)- 1,5 -naphthyridin-2-yl)oxy)methyl)pyrrolidin- 1 -yl)propoxy)propanoyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2-yl)piperidine-2, 6-dione (49) as a tan solid: HRMS HPLC-MS (ES+) m / z [M+H+] calcd. for C69H9oFNio07Si, 1217.6747; found, 1217.6737.

[0335] (S)-3-(5-(4-((l-(3-(3-((S)-2-(((4-((lR,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoyl)piperidin-4-yl)methyl)piperazin-l-yl)-l-oxoisoindolin-2-yl)piperidine-2, 6-dione (4b). Cesium fluoride (142 mg, 0.94 mmol) was added to a solution of (S)-3-(5-(4-((l-(3-(3-((S)-2-(((4-((lR,5S)-3,8-Attorney Docket No. BPR0115PCT

[0336] diazabicyclo[3.2.1]octan-3-yl)-7-(7-fluoro-3-hydroxy-8- ((triisopropylsilyl)ethy nyl)naphthalen- 1 -yl)- 1,5 -naphthyridin-2-y l)oxy)methyl)pyrrolidin- 1 -yl)propoxy)propanoyl)piperidin-4-yl)methyl)piperazin-l-yl)-l-oxoisoindolin-2-yl)piperidine-2, 6-dione (49; 133 mg, 0.11 mmol) in anhydrous DMF (3.6 mL) and the mixture stirred at RT. After 16 h, the mixture was diluted with EtOAc, washed with water (4X), dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluting with a gradient of 0% to 20% MeOH in DCM containing 10% NH4OH (v / v)) to afford 25.6 mg (22%) of (S)-3-(5-(4-((l-(3-(3-((S)-2-(((4-((lR,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-l-yl)-l,5-naphthyridin-2-yl)oxy)methyl)pyrrolidin-l-yl)propoxy)propanoyl)piperidin-4-yl)methyl)piperazin-l-yl)-l-oxoisoindolin-2-yl)piperidine-2, 6-dione (50) as a tan solid: HRMS HPLC-MS (ES+) m / z: [M+H+] calcd. for C60H70FN10O7, 1061.5413; found, 1061.5387; ’H NMR (300 MHz, DMSO-d6) 511.0 (br s, 1H), 10.2 (br s, 1H), 8.56 (d, J = 2.1 Hz, 1H), 7.97 (dd, J= 9.2, 6.0 Hz, 1H), 7.88 (q, J = 2.6 Hz, 1H), 7.48 (dd, J = 18.5, 9.2 Hz, 2H), 7.35 (d, J = 2.6 Hz, 1H), 7.11 (br d, J = 2.5 Hz, 1H), 7.02 (br s, 2H), 6.24 (s, 1H), 5.05 (dd, J= 13.2, 5.1 Hz, 1H), 4.61 (d, J = 11.1 Hz. 1H), 4.45 -4.36 (m, 2H), 4.32 (d, J = 17.0 Hz, 2H), 4.19 (d, J= 16.9 Hz, 2H), 4.06 (brs, 1H), 3.96- 3.83 (m, 2H), 3.71 (brs, 1H), 3.51 (br s, 2H), 3.45 - 3.34 (m, 2H), 3.20 (br s, 4H), 3.07 - 2.89 (m, 6H), 2.87 - 2.69 (m, 3H), 2.59 (br d, J= 16.0 Hz, 1H), 2.45 - 2.25 (m, 10H), 2.16 (d, J= 7.8 Hz, 1H), 2.06 (br s, 2H), 2.00 -1.80 (m, 4H), 1.78 - 1.51 (m, 10H).

[0337] The CRBN ligand(54) can be prepared according to the synthetic method described in Scheme 7.Attorney Docket No. BPR0115PCT

[0338] Scheme 7

[0339] 53

[0340] 4 M HCI

[0341]

[0342] 1,4-dioxane 54

[0343] tert-butyl (S)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1-carboxylate (53). Sodium triacetoxyborohydride (1.16 g, 5.48

[0344] mmol) was added to a mixture of (S)-3-(l-oxo-5-(piperazin-l-yl)isoindolin-2-yl)piperidine-2, 6-dione hydrochloride (51; CAS #: 2520107-65-5; 1.0 g, 2.74 mmol) and tert-butyl 4-formylpiperidine-1 -carboxylate (52; CAS #: 137076-22-3; 700 mg, 3.29 mmol) in anhydrous THF (10 mL) cooled to 0°C under a N2 atmosphere. Acetic acid (24 pL) was added and the suspension warmed and stirred at RT under a N2 atmosphere. After 16 h, additional tert-butyl

[0345] 4-formylpiperidine-l -carboxylate (236 mg) was added and the mixture cooled to 0°C.

[0346] Another portion of sodium triacetoxyborohydride (313 mg) was added and the suspension warmed and stirred at RT. After 16 h, the mixture was diluted with DCM containing a small amount of MeOH and the reaction quenched with water. After stirring RT for 10 minutes, the layers were separated. The aqueous layer was extracted with DCM (4X), the organics

[0347] combined, dried (MgSC ), filtered, and concentrated in vacuo. The crude product was

[0348] purified by silica gel column chromatography (eluting with a gradient of 1% to 10% MeOH

[0349] in DCM to afford 1.0 g (69%) of tert-butyl (S)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-yl)methyl)piperidine-l -carboxylate (53) as a white solid:

[0350] HRMS HPLC-MS (ES+) m / z [M+H+] calcd. for C28H40N5O5, 526.3029; found, 526.3021; ‘H NMR (300 MHz, DMSO-d6) 8 11.0 (s, 1H), 7.52 (d, J = 9.2 Hz, 1H), 7.10 - 7.00 (m, 2H),

[0351] 5.05 (dd, J = 13.2, 5.0 Hz, 1H), 4.26 (dd, J = 39.2, 16.7 Hz, 2H), 3.93 (br d, J = 12.9 Hz, 2H), 3.27 (br t, J = 5.0 Hz, 4H), 2.90 (ddd, J= 17.1, 13.6, 5.3 Hz, 1H), 2.70 (br s, 2H), 2.57 (br d,Attorney Docket No. BPR0115PCT

[0352] 7 = 16.2 Hz, 1H), 2.48 - 2.43 (m, 4H), 2.35 (tt, 7 = 13.3, 6.6 Hz, 1H), 2.17 (d, 7 = 6.7 Hz, 2H), 2.01 - 1.91 (m, 1H), 1.69 (d, 7= 11.9 Hz, 3H), 1.39 (s, 9H), 1.05 - 0.84 (m, 2H).

[0353] (S)-3-(1-oxo-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione dihydrochloride (54). A suspension of tert-butyl (S)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1-carboxylate (53; 1.0 g, 1.90 mmol) in 4 M HC1 in dioxane (9.4 mL) was stirred at RT under a N2 atmosphere. After 3 h, the mixture was diluted with DCM, the solid filtered, and washed with DCM. The solid was dissolved in MeOH and concentrated in vacuo to afford 0.83 g (88%) of (S)-3-(1-oxo-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione dihydrochloride (54) as a white solid: HRMS HPLC-MS (ES+) nt / z [M+H+] calcd. for C23H32N5O3. 426.2505; found, 426.2497; ’H NMR (300 MHz, DMSO-d6) 511.1 (br s, 1H), 11.0 (s, 1H), 9.21 - 8.80 (m, 2H), 7.59 (d,7= 8.4Hz, 1H), 7.22 -7.11 (m, 2H), 5.07 (dd, 7= 13.2, 5.1 Hz, 1H), 4.3O (dd, 7= 39.7, 17.1 Hz, 2H), 3.95 (br s, 2H), 3.60 (brd, 7= 11.9 Hz, 2H), 3.48 (brt, 7= 12.5 Hz, 2H), 3.26 (br d, 7 = 12.6 Hz. 2H), 3.14 - 3.00 (m, 4H), 3.00 - 2.75 (m, 3H), 2.60 (br d, 7 = 16.2 Hz, 1H), 2.38 (tt, J = 13.3, 6.6 Hz, 1H), 2.19 (brs. 1H), 2.10 - 1.91 (m, 3H), 1.46 (q, 7 = 11.7 Hz, 2H).

[0354] 2-((S)-l-acryloyl-4-(7-(8-chloronaphthalen-l-yl)-2-(((S)-l-(3-(3-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)propyl)pyrrolidin-2-yl)methoxy)-3-fluoro-1,5-naphthyridin-4-yl)piperazin-2-yl)acetonitrile (5b)

[0355]

[0356] Attorney Docket No. BPR0115PCT

[0357] Compound 5b can be prepared according to the synthetic method described in Scheme 8.

[0358] Selectfluor CH3CN CH2CI2

[0359] LIOH THF

[0360] MeOH H2O

[0361]

[0362] Attorney Docket No. BPR0115PCT

[0363]

[0364] 61Attorney Docket No. BPR0115PCT

[0365] Et3N CH2CI2

[0366]

[0367] 5b

[0368] As shown in Scheme 8, treatment of 19 with an electrophilic fluorination reagent such as Selectfluor in a mixture of CH3CN and dichloromethane affords the fluorinated intermediate 55. Nucleophilic displacement with alcohol 28 in the presence of a base such as NaOtBu in THF affords intermediate 56. Treatment of 56 with iodide 27 in the presence of a base such as EtaN in DMF affords compound 57. Suzuki coupling of intermediate 57 with boronate 22 in the presence of a ligand such as CataCXium A and catalyst such as CataCXium A Pd G2 and a base such as K2CO3in a mixture of toluene and water at elevated temperature affords intermediate 58. Saponification of 58 with a base such as LiOH in a mixture of THF, MeOH, and H₂O affords intermediate 59. Coupling of 59 with amine 38 in the presence of HOBt monohydrate, EDC hydrochloride, and a base such as EtiN in DMF affords intermediate 60. Removal of the Boc protecting group on 60 under acidic conditions with an acid such as TFA in dichloromethane affords the amine 61 followed by treatment with 25 in the presence of a base such as Et₃N in dichloromethane will afford compound 5b.

[0369] Biological Assay Data for Compound 3b

[0370] Compound 3b (10 uM) and positive control compound (LC-2, 2.5 uM) were tested against KRAS (G12C) in MIA PaCa-2 cells in single dose singlet format by Western blot.Attorney Docket No. BPR0115PCT

[0371] Treatment time: 24 and 72 hours

[0372] Western Blot Assay of

[0373] KRAS (G12C)

[0374] MIA PaCa-2 cells were treated with the

[0375] following compounds for 24 and 72 hours.

[0376] Data for Western blot band

[0377] density analysis

[0378] 24 h

[0379] MIA PaCa-2 cells

[0380] KRAS Normalized KRAS (G12C) a-Tubulin

[0381] Cone. (G12C) / a- KRAS (G12C)

[0382] (Band density)

[0383] (pM) (Band density) Tubulin (%) DMSO 1.41 6.08 0.23 100.00 Compound

[0384] 3b (10 uM) 0.20 4.48 0.05 19.59 LC-2 (2.5

[0385]

[0386] uM) 0.15 4.55 0.03 14.06

[0387] 72 h

[0388] MIA PaCa-2 cells

[0389] KRAS Normalized KRAS (G12C) a-Tubulin

[0390] Cone. (G12C) / a- KRAS (G12C)

[0391] (Band density)

[0392] (pM) (Band density) Tubulin (%) DMSO 1.33 4.65 0.29 100.00 Compound

[0393] 3b (10 uM) 0.29 4.26 0.07 24.17 LC-2 (2.5

[0394]

[0395] uM) 0.24 4.52 0.05 18.52

[0396] Western Blot band density analysis is shown in Figs 1 and 2. Gel profiles of the Western Blot are shown in Figs. 3 and 4. DMSO was used as a control. Positive control compound LC-2 has the structureAttorney Docket No. BPR0115PCT

[0397]

[0398] Lanes marked with “849” in Figs 5-7 refers to MRTX849 (Adagrasib) from Mirati, a potent, orally available, and mutation-selective covalent inhibitor of KRAS G12C with potential anti neoplastic activity. These lanes were included as a check on cell viability under the test conditions. MTRX849 has the structure:

[0399]

[0400] Nucleotide Exchange Assays

[0401] The biological activity of the Examples was determined in a SOS1 Nucleotide Exchange Assay that was performed by Reaction Biology Corporation (RBC), 1 Great Valley Parkway, Suite 2 Malvern, PA 19355, USA. The assay evaluates the SOSl-mediated Bodipy-GDP to GTP exchange observed with KRAS G12C.

[0402] The compounds were tested in 10 concentration IC50 mode with 3-fold serial dilution at a starting concentration of 5 pM for ARS1620 and 10 pM for Examples 1-4, MRTX849 and MRTX1133. The compound pre-incubation time was 30 min at RT and the curve fits were performed when the activities at the highest concentration of compounds were less than 65%.Attorney Docket No. BPR0115PCT

[0403] Reaction Buffer: 40 mM HEPES 7.4, 10 mM MgCl2, 1 mM DTT 0.002% Triton X100, 0.5% DMSO.

[0404] Enzyme: SOS 1 (RBC cat# MSC-11-502). Recombinant human SOS 1 (Genbank accession# NM_033360.3; aa 564-1049, expressed in E. Coli with C-terminal StrepII).

[0405] KRAS G12C: Recombinant human KRAS G12C (aa 2-169, expressed in E. coli with A-terminal TEV cleavable his-tag) was pre-loaded with a 5-fold excess of Bodipy™-GDP and the excess Bodipy-™GDP was removed from loaded protein using a spin desalting column.

[0406] Final concentrations: KRAS-Bodipy™-GDP was 0.125 pM; S0S1 was 750 nM; and GTP was 25 pM.

[0407] Reaction Procedure:

[0408] 1. Deliver 10 uL of 1.5x KRAS solution in freshly prepared reaction buffer to reaction wells.

[0409] 2. Deliver compounds in 100% DMSO into buffer using acoustic technology (Echo550; nanoliter range).

[0410] 3. Incubate compounds with KRAS for 30 minutes at room temperature.

[0411] 4. Prepare 3x (SOS1 + GTP) solution in reaction buffer.

[0412] 5. Deliver 5 pL of SOS1+GTP solution into reactions wells (deliver GTP only to column 1 for no SOS1 control).

[0413] 6. Monitor reaction progress via decrease in fluorescence signal for 30 minutes at RT using a PHERAstar (BMG Labtech plate reader (Ex / Em = 485 / 520).

[0414] Data Analysis: The fluorescence data was normalized using the equation below and fitted to “one phase exponential decay” equation using GraphPad prism software. The plateau was fixed to zero (used for non-covalent inhibitors) and rate xlOOO was used to calculate the IC50 values.

[0415] (Yraw — Ao)

[0416] Ynorm =

[0417]

[0418] where Yraw is defined as fluorescence at time t, Ao is the average initial fluorescence with no SOS 1, and M is the minimum fluorescence at the end of the reaction at the maximum SOS 1.

[0419] The background subtracted signals (no SOS1 protein wells were used as background) were converted to % activity relative to DMSO controls. Data was analyzed using GraphPadAttorney Docket No. BPR0115PCT

[0420] Prism 4 with “sigmoidal dose-response (variable slope)’’; 4 parameters with Hill Slope. The constraints were bottom (constant equal to 0) and top (must be less than 120).

[0421] Results:

[0422] KRAS G12C Activity

[0423] Example ICso (nM)’ ARS-1620 100 ± 17 (n = 8) MRTX-849 28 + 3 (zi = 8)

[0424] 2b 38 ± 17a 130

[0425]

[0426] TCso values were calculated using the dRFU analysis method for covalent inhibitors with Bodipy-GDP / KRAS G12C as the substrate with 0.5% DMSO in the reaction. ARS-1620 and MRTX-849 are KRAS G12C reference standards.

[0427] KRAS G12C Cellular Assay

[0428] KRAS G12C cellular activity was determined in a target engagement cellular assay (NanoBRET™) in transiently transfected HEK293 cells by Reaction Biology Corporation (RBC), 1 Great Valley Parkway, Suite 2 Malvern, PA 19355, USA. HEK293 were cultivated to 70-80% confluence prior to the assay followed by trypsinizing and collection of the cells. BI-2852 was used as the KRAS G12C reference compound. Each test compound solution was delivered from a compound source plate to the wells of 384-well white non-binding surface plate by an Echo 550 prior to the assay.

[0429] A 10 pg / mL solution of DNA in Opti-MEM was prepared without serum that consisted of 1 pg LgBiT®-KRAS (G12C)-NanoLuc fusion vector, 1 pg SmBiT®-KRAS (G12C)-NanoLuc fusion vector and 8 pg transfection carrier DNA. This mixture was subsequently treated with 30 pL of FuGENE HD Transfection Reagent into each milliliter of DNA mixture to form a lipid: DNA complex. The resulting mixture was then gently mixed by inversion and incubated at ambient temperature for 20 minutes to allow complexes to form. A mixture of 1 part of lipid: DNA complex with 20 parts of suspended HEK293 cells was added to a sterile conical tube and mixed gently by inversion. The cells + lipid: DNAAttorney Docket No. BPR0115PCT

[0430] complex mixture was then added to a sterile tissue culture dish and incubated for 24 hours. The medium was removed from the dish via aspiration followed by trypsinizing and allowing the cells to dissociate from the tissue culture dish. The trypsin was subsequently neutralized by using medium containing serum and centrifugation at 200xg for 5 minutes to pellet the cells in the conical tube. The cell density was adjusted to 2 x 105 cells / mL in Opti-MEM without phenol red. One part of Complete 20X NanoBRET™ RAS Tracer Reagent was dispensed to 20 parts of cells in the conical tube and mixed gently by inversion. The resulting cell suspension was dispensed into a white, 384-well NBS plate containing the test compounds (starting at 10 pM, 10-dose with 3-fold dilution) at 37°C, 5% CO2 for 2 hours. The final concentration for RAS tracer K2 was 1 pM. The NBS plate was removed from the incubator and allowed to equilibrate to room temperature for 15 minutes.

[0431] Freshly prepared substrate solution (3X) in the assay medium was added to each well of the 384-well NBS plate and incubated for 3 minutes at room temperature. The donor emission wavelength (460 nm) and acceptor emission wavelength (600 nm) were measured using an Envision 2104 plate reader. The raw BRET ratio values were generated by dividing the acceptor emission value (600 nm) by the donor emission value (460 nm) for each sample. In order to correct for the background, the BRET ratio in the absence of tracer (average of notracer control samples) was subtracted from the BRET ratio of each sample. The BRET ratio was calculated using the following equation: BRET Ratio = [(Acceptor sample - Donor sample) - (Acceptor no-tracer control - Donor no-tracer control)]. The normalized BRET response (%) was calculated by the following equation: (BRET ratio of test compound / BRET ratio of DMSO control) *100%. The IC50 curves were plotted and IC50 values were calculated with GraphPad Prism 4 based on a sigmoidal dose-response equation.Attorney Docket No. BPR0115PCT

[0432] Results:

[0433] KRAS G12C Inhibition in NCI-H358 Cells*

[0434] Example RelCso (pM) AbsICso (pM) LC-2 1.03 1.03 MRTX-849 0.15 0.08 Example 1

[0435] 0.28 0.28

[0436] (lb)

[0437] Example 2

[0438] 0.95 0.95

[0439]

[0440] (2b)

[0441] KRAS G12C Inhibition in MIA-PaCa-2 Cells* Example RelCso (pM) AbsICso (pM) LC-2 3.47 3.47 MRTX-849 0.43 0.43 Example 1

[0442] 0.98 0.88

[0443] (lb)

[0444] Example 2

[0445] 1.44 1.42

[0446]

[0447] (2b)Attorney Docket No. BPR0115PCT

[0448] KRAS G12C Activity in Transiently Transfected HEK293 Cells* Compound IC₅₀(nM) BI-2852 320

[0449] Example 1

[0450] 4.4

[0451] (Compound 2b)

[0452] Example 5

[0453] < 0.5

[0454] (1ae)

[0455] Example 6

[0456] 334

[0457] (1af)

[0458]

[0459] NanoBRET™ target engagement cellular assay (KRAS G12C). BI-2852 is a KRAS G12C reference standard.

[0460] CellTiter-Glo Viability Assay Protocol

[0461] Materials:

[0462] The reference compound staurosporine was purchased from Sigma-Aldrich (Saint Louis, MI). CellTiter-Glo® 2.0 Luminescent cell viability assay reagent was purchased from Promega (Madison, WI). MIA PaCa-2 cell line was purchased from American Type Culture Collection (Manassas, VA). MIA PaCa-2 cells were cultured in DMEM containing 10% FBS, 2.5% horse serum, 100 µg / ml of penicillin and 100 µg / ml of streptomycin. Cultures were maintained at 37 °C in a humidified atmosphere of 5% CO2 and 95% air.

[0463] Procedure:

[0464] 1. Test compounds and reference compound, staurosporine, were diluted in DMSO solution with 10-dose and 3-fold dilution in a source plate starting at 10 mM.

[0465] 2. 25 nL of test compounds or 25 nL of staurosporine was delivered from the source plate to each well of the 384-well cell culture plate by Echo 550.

[0466] 3. 25 pL of culture media containing 2000 cells was added to each of the wells of the cell culture plate in duplicate.

[0467] 4. The cells were incubated with the compounds at 37°C, 5% CO2 for 72 hours.

[0468] 5. 25 |iL of CellTiter-Glo 2.0 reagent was added to each well.

[0469] 6. The contents were mixed on an orbital shaker for 2 min and incubated at room temperature for 15 min to stabilize luminescent signal.

[0470] 7. Luminescence was recorded by Envision 2104 Multilabel Reader (PerkinElmer, Santa Clara, CA). The number of viable cells in culture was determined based on quantitation of the ATP present in each culture well.

[0471] 8. The IC50 curves were plotted and IC50 values were calculated using the GraphPad Prism 4 program based on a sigmoidal dose-response equationAttorney Docket No. BPR0115PCT

[0472] Results:

[0473] CTG Assay IC50 Values (M)

[0474] Compound / Cell Line MIA PaCa-2

[0475] MRTX-849 1.52E-06

[0476] Example 5

[0477] lae 2.88E-06

[0478] Staurosporine 2.49E-07

[0479]

[0480] PK Profile in male CD1 mice:

[0481] Analyte lae

[0482] 3mg / kg, i.v., single 30mg / kg, p.o., single

[0483] Group dose dose

[0484] (20% DMSO / 30% (1% Tween 80 / 2%

[0485] PEG400 / 50% ddH₂O) HPMC / 97% H₂O)

[0486] Matrix Mean Plasma Mean Plasma

[0487] Dosage (mg / kg) 3.00 30.0

[0488] Rsq_adj 0.955 0.993

[0489] No. points used for T1 / 2 6.00 5.00

[0490] Co (ng / mL) 800

[0491] Cmax (ng / mL) 249

[0492] Tmax (h) 1.00

[0493] T1 / 2 (h) 1.42 2.85

[0494] Vdss(L / kg) 7.70

[0495] Cl(mL / min / kg) 72.4

[0496] Tlast (h) 8.00 24.0

[0497] AUCo-last (ng-h / mL) 673 1495

[0498] AUCo-inf (ng.h / mL) 691 1499

[0499] MRTo-last (h) 1.56 4.72

[0500] MRTo-inf (h) 1.77 4.79

[0501] AUC Extra(%) 2.52 0.315

[0502] AUMC. Extra(%) 14.3 1.85

[0503]

[0504] Bioavailability (%) 21.7

Claims

1. Attorney Docket No. BPR0115PCTCLAIMSWHAT IS CLAIMED IS;1. A compound of Formula I:R2GFormula Ior a pharmaceutically acceptable salt, solvate, or prodrug thereof, whereinA is chosen from aryl or heteroaryl optionally substituted with one or more of hydrogen, halogen, hydroxy, -Ci-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -C0-3 alkyl(C3-6 cycloalkyl), -C1-6 alkyl(halo), -Ci-6 alkyl(OH), -O(Ci-4alkyl), -C1-3 alkyl(Ci-4alkoxy), -CN, -CO2R4,-CO2N(R4)2, -NO2, -N(R4)2, -P(O)(R5)2, -SR4, -S(O)R4, -SO2R4or a 5-6 membered heterocyclic ring;Y and G may be the same or different and chosen from hydrogen, halogen, C1-4 alkyl, Ci -4 perdeuteroalkyl, -(C0-2 alkyl)alkenyl, -(C0-2 alkyl)alkynyl, -(C0-2 alkyl)cycloalkyl, -C1-4 haloalkyl, -O(Ci-4 alkyl), -S(Ci-4 alkyl), -(C0-2 alkyl)cyano, -O(Ci-4haloalkyl) or -S(Ci- 4 haloalkyl);L is a bond, O, S, or NR4;m is 0-2;nis 0-2;Z is C(R4)2 or a cyclic compound chosen from C3-7 cycloalkyl, a saturated or partially unsaturated 4- to 7-membered nitrogen-containing ring, a saturated or partially unsaturated 7- to 10-membered nitrogen-containing bridged bicyclic ring, wherein the saturated or partially unsaturated 7- to 10-membered nitrogen-containing bridged bicyclic ring may be substituted by halogen, preferably F, or unsubstituted;Attorney Docket No. BPR0115PCTR1is chosen from hydrogen, hydroxy, halogen, -C1-3 alkyl, -C1-3 alkyl(OH), -C1-3 alkyl(halo), -C1-3 alkyl(Ci-3alkoxy), -C1-3 alkyl(CN) or -C1-3 alkyl(P(O)R52);R2is chosen from hydrogen, -C(O)CH=CH, -C(O)CF=CH or -C(O)CC1=CH with the proviso that when R2is hydrogen, then m is either 1 or 2;R3is chosen from hydrogen, halogen, hydroxy, -C1-4 alkyl, -C2-4 alkenyl, -C2-4 alkynyl, -C0-3 alkyl(C -6 cycloalkyl), -C1-4 alkyl(halo), -Ci-4alkyl(OH), -O(Ci-4alkyl), -C1-3 alkyl(Ci-3alkoxy), -CN, -CO2R4, -CO2N(R4)2, -NO2, -N(R4)2, -PO(R5)2, -SR4,-S(O)R4, -SO2R4, or -(C0-3 alkyl)R6, a VHL E3 ligase ligand, or a Cereblon (CRBN) E3 ubiquitin ligase; R4is chosen from is chosen from hydrogen, C1-4 alkyl, aryl or heteroaryl;R5is chosen from hydrogen, hydroxy, C1-4 alkyl, aryl, heteroaryl, C1-4 alkoxy, aryloxy or heteroaryloxy;R6is chosen from N(R4)2or a 4- to 7-membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group N, O and S; andR7is chosen from hydrogen and halogen.

2. The compound of claim 1 wherein the compound of Formula I is selected from compounds la-c-30a-c, including a pharmaceutically acceptable salt, solvate, or prodrug thereof:Attorney Docket No. BPR0115PCTAttorney Docket No. BPR0115PCTAttorney Docket No. BPR0115PCT3. The compound of claim 1 wherein the compound of Formula 1 isor a pharmaceutically acceptable salt, solvate, or prodrug thereof.Attorney Docket No. BPR0115PCT4. The compound of claim 1 wherein the compound of Formula I is Formula IVGFormula IVincluding pharmaceutically acceptable salts, solvates, or prodrugs thereof.

5. The compound of claim 4, wherein the compound of Formula IV is FormulaAttorney Docket No. BPR0115PCT6. The compound of claim 4, wherein the compound of Formula IV is Formula Va:

7. The compound of claim 1, having the structure8. The compound of claim 1, further comprising a PROTAC linker.Attorney Docket No. BPR0115PCT9. The compound of claim 8, wherein the PROTAC linker is a VHL E3 ligase ligand or a Cereblon (CRBN) E3 ubiquitin ligase.

10. The compound of claim 9, wherein the wherein the VHL E3 ligase ligand is (2S,4R)-l-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide.

11. The compound of claim 10, wherein the Cereblon E3 ubiquitin ligase is 3-(l- oxo-5-(4-((l-(3-(3-(pyrrolidin-l-yl)propoxy)propanoyl)piperidin-4- yl)methyl)piperazin-l-yl)isoindolin-2-yl)piperidine-2, 6-dione.

12. A pharmaceutical composition comprising the compound of any one of Claims 1 to 7, or a salt, solvate, or prodrug thereof, together with a pharmaceutically acceptable carrier.

13. A method of treating a disease, disorder, or medical condition in a patient, comprising the step of providing to a patient in need thereof a therapeutic agent, wherein the therapeutic agent is a compound of any one of claims 1 to 7, or a salt, solvate, or prodrug thereof.

14. The method of treating a disease, disorder, or medical condition of claim 13, wherein said disease includes various cancers.

15. The method of treating a disease, disorder, or medical condition of claim 14, wherein said disease, disorder, or medical condition is mediated through KRAS.

16. The method of treating a disease, disorder, or medical condition of claim 14, wherein said disease, disorder, or medical condition is mediated through the KRAS mutant G12C or KRAS mutant G12D.

17. The method of treating a disease, disorder, or medical condition of claim 14, wherein the cancer is selected from glioma (glioblastoma), acute myelogenous leukemia, acute myeloid leukemia, myelodysplastic / myeloproliferative neoplasms, sarcoma, chronic myelomonocytic leukemia, non-Hodgkin lymphoma, astrocytoma, melanoma, non-small cellAttorney Docket No. BPR0115PCTlung cancer, small cell lung cancer, cholangiocarcinomas, chondrosarcoma, colon cancer, colorectal cancer, rectal cancer or pancreatic cancer.

18. The method of any one of claims 13-17, further comprising administering to the patient in need thereof at least one additional therapeutic agent.

19. The method of claim 18, wherein the additional therapeutic agent is selected from the group consisting of doxorubicin, paclitaxel, docetaxel, cisplatin, camptothecin, temozolomide, avastin, Herceptin, Erbitux, EGFR inhibitors, osimertinib, rezivertinib, CDK 4 / 6 inhibitors, abemaciclib, palbociclib, ribociclib, c-MET inhibitors, capmatinib, volitinib, ALK inhibitors, crizotinib, alectinib, ceritinib, brigatinib, entrectinib, lorlatinib, PD-1 antagonists, PD-L1 antagonists, ipilimumab, embrolizumab, or nivolumab.

Images